A benzothiazolylpyrimidine amine DYRK2 inhibitor and its preparation method and application

By designing and synthesizing benzothiazole pyrimidinamine compounds, it provides high-active DYRK2 inhibitors, solves the problem of insufficient activity of existing DYRK2 inhibitors, significantly inhibits the proliferation of DYRK2 kinase and cancer cells, and demonstrates safe and efficient anti-cancer effects. .

CN118146213BActive Publication Date: 2024-11-26JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310816625.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-12-06
Filing Date
2023-07-05
Publication Date
2024-11-26
Estimated Expiration
2043-07-05

AI Technical Summary

Technical Problem

The existing DYRK2 inhibitor activity is not ideal, and it is urgent to provide higher-active DYRK2 inhibitors for the treatment of related cancers.

Method used

A benzothiazole pyrimidinamine-based DYRK2 inhibitor is provided. Through specific compound structure and synthesis methods, DYRK2 small molecule inhibitors with strong inhibitory activity are prepared. The IC50 value can reach 0.1nM-1000nM, and the preferred value is 1nM-100nM. Within range.

Benefits of technology

Effective inhibition of DYRK2 kinase activity was achieved, significantly reduced cancer cell proliferation, demonstrated good anti-cancer effects, and showed good safety in acute toxicity tests.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118146213B_ABST
    Figure CN118146213B_ABST
Patent Text Reader

Abstract

The present invention discloses a benzothiazolylpyrimidine amine DYRK2 inhibitor and its preparation method and application. The compound of the present invention can inhibit the proliferation of cancer cells and can be used to prepare drugs for treating cancer or tumor-related diseases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicinal chemistry, and in particular to a benzothiazolylpyrimidineamine DYRK2 inhibitor and a preparation method thereof, as well as use thereof in preparing drugs for treating related diseases. Background Art

[0002] Human dual-specificity tyrosine-phosphorylation-regulated kinases (DYRKs) are an evolutionarily conserved kinase family characterized by their kinase activity on their own tyrosine residues and serine / threonine sites of other proteins. DYRKs belong to the serine / threonine CMGC kinase family, which has five members. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) belongs to the DYRK family and has both tyrosine kinase activity and serine / threonine kinase activity, and has multiple functions in regulating cell proliferation, apoptosis, and differentiation.

[0003] Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) belong to the CMGC kinase group together with CDK and MAPK family kinases. In the human body, there are 5 subtypes of DYRK family kinases. Among them, DYRK2 is an important regulator of 26S protein kinase, which phosphorylates the Thr25 site of the Rpt3 subunit in the 26S proteasome regulatory particle, thereby enhancing the activity of the proteasome. DYRK2 was found to have significantly increased expression levels in tumors and plays an important role in tumor proliferation and growth. At present, DYRK2 small molecule inhibitors play a significant anti-cancer effect in cancers such as prostate cancer, triple-negative breast cancer and multiple myeloma. Recently, a research group reported a DYRK2-specific small molecule inhibitor, LDN192960 (Banerjee et al., 2019). Crystal structure analysis and biochemical studies revealed the molecular mechanism of LDN192960's selective inhibition of DYRK2. LDN192960 can reduce proteasome activity by inhibiting the activity of DYRK2, thereby alleviating the progression of triple-negative breast cancer and multiple myeloma, indicating that targeting DYRK2 is expected to become an effective treatment for these two tumors.

[0004] However, the activity of DYRK2 inhibitors in the prior art is still not ideal, and there is an urgent need to provide a DYRK2 inhibitor with better activity. Summary of the invention

[0005] The object of the present invention is to provide a DYRK2 small molecule inhibitor, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the DYRK2 small molecule inhibitor and a preparation method thereof, and use thereof in the preparation of a drug for treating related cancers or tumor diseases.

[0006] The present invention provides a compound as shown in formula (P), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,

[0007]

[0008] in,

[0009] The X are independently selected from: O, NH, S(O)2, C(O) or -(CH2) n -, n is 0 or 1 or 2;

[0010] The A, B, and C are independently selected from: C or N;

[0011] The R1s are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, nitro, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, C5-C 10 heteroaryl, C4-C8 heterocyclic group or -NR4R5, wherein R4 and R5 are independently selected from: H, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, C5-C 10 Heteroaryl or C4-C8 heterocyclic group;

[0012] The R2 is independently selected from hydrogen, deuterium, hydroxyl, thiol, cyano, halogen, nitro, C3-C8 cycloalkyl, C1-C8 alkyl or C1-C8 alkoxy;

[0013] The R3 are independently selected from hydrogen, deuterium, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, -C(O)OC1-C8 alkyl, -C(O)C3-C8 cycloalkyl, C6-C 10 Aryl, C3-C 10 Heteroaryl, C4-C8 heterocyclyl or -C(O)R6;

[0014] The R6 are independently selected from C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or C6-C 10 Aryl.

[0015] Preferably, the compound represented by (P), or its stereoisomer, or its pharmaceutically acceptable salt is a compound represented by the following formula (PI) or (P-II), or its stereoisomer, or its pharmaceutically acceptable salt:

[0016]

[0017] in:

[0018] X is independently selected from: O, NH, S(O)2, C(O) or -(CH2) n -, n is 0 or 1 or 2;

[0019] The A, B, and C are independently selected from: C or N;

[0020] The R1s are independently selected from the group consisting of hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, nitro, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, C6-C 10 Aryl, C3-C 10 heteroaryl, C4-C8 heterocyclic group or -NR4R5, wherein R4 and R5 are independently selected from: H, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, C3-C 10 Heteroaryl or C4-C8 heterocyclic group;

[0021] The R2 is independently selected from hydrogen, deuterium, hydroxyl, thiol, cyano, halogen, nitro, C3-C8 cycloalkyl, C1-C8 alkyl or C1-C8 alkoxy;

[0022] The R3 are independently selected from hydrogen, deuterium, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, -C(O)OC1-C8 alkyl, -C(O)C3-C8 cycloalkyl, C6-C 10 Aryl, C3-C 10 Heteroaryl, C4-C8 heterocyclyl or -C(O)R6;

[0023] The R6 are independently selected from C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl or C6-C 10 Aryl.

[0024] Preferably, the compound represented by formula (PI) or (P-II), or its stereoisomer, or its pharmaceutically acceptable salt:

[0025] in,

[0026] The X are independently selected from C(O) or -(CH2) n-, n is 1;

[0027] A, B, and C are independently selected from C or N;

[0028] The R1 is independently selected from hydrogen, halogen, C1-C8 alkyl, hydroxyl, -NR4R5, wherein R4 and R5 are selected from H, C1-C6 alkyl or C4-C8 heterocyclic group;

[0029] The R2 are independently selected from hydrogen, halogen, hydroxyl, C1-C6 alkyl or C1-C6 alkoxy;

[0030] The R3 are independently selected from hydrogen, C1-C6 alkyl, -C(O)OC1-C6 alkyl, -C(O)C3-C6 cycloalkyl, C6-C 10 Aryl, or -C(O)R6;

[0031] The R6 are independently selected from C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl or C6-C 10 Aryl.

[0032] More preferably, the compound represented by formula (PI) or (P-II), or its stereoisomer, or its pharmaceutically acceptable salt:

[0033] in:

[0034] The X's are independently selected from C(O) or -CH2-;

[0035] A, B, and C are independently selected from C or N;

[0036] The R1 is selected from hydrogen, methyl or -NR4R5, wherein R4 and R5 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopentyl or cyclohexyl;

[0037] The R2 are independently selected from hydrogen, methyl, ethyl, propyl, methoxy, fluorine or isopropyl;

[0038] The R3 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, -C(O)OC1-C6 alkyl, phenyl or -C(O)R6;

[0039] The R6 are independently selected from methyl, ethyl, methoxy, ethoxy or cyclopropyl.

[0040] Most preferably: the compound represented by formula (PI) or (P-II), or its stereoisomer, or its pharmaceutically acceptable salt, is selected from the compounds, or its stereoisomer, or its pharmaceutically acceptable salt having the following structures:

[0041]

[0042]

[0043]

[0044]

[0045]

[0046]

[0047]

[0048]

[0049] The present invention also provides a compound represented by formula (P), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:

[0050] Wherein, the pharmaceutically acceptable salt is a salt formed by the compound represented by formula (P) and hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, trichloroacetic acid, propionic acid, butyric acid, maleic acid, p-toluenesulfonic acid, malic acid, malonic acid, cinnamic acid, citric acid, fumaric acid, camphoric acid, digluconic acid, aspartic acid and tartaric acid. Preferably, the pharmaceutically acceptable salt is the hydrochloride of the compound of general formula (P).

[0051] The present invention also provides a method for preparing a compound represented by general formula (P), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, comprising the steps of coupling reaction of an intermediate compound (A) with an intermediate compound (B) under the action of a catalyst:

[0052]

[0053] wherein the substituents of X, A, B, C, R1, R2 and R3 are defined as above;

[0054] Preferably, the catalyst is a palladium catalyst;

[0055] Preferably, the reaction is carried out under an argon protective atmosphere; the reaction temperature is 55-125° C., and the reaction time is 5-24 hours.

[0056] The present invention also provides a pharmaceutical composition comprising the compound represented by formula (P), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

[0057] The present invention also provides the use of the compound represented by formula (P), or its stereoisomer, or its pharmaceutically acceptable salt, or the pharmaceutical composition comprising the compound represented by formula (P), or its stereoisomer, or its pharmaceutically acceptable salt in the preparation of drugs for DYRK2 target inhibitors.

[0058] The DYRK2 target inhibitor is a drug for treating cancer or tumor-related diseases, preferably a drug for treating or preventing lung cancer, leukemia, breast cancer, prostate cancer, multiple myeloma, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer or endometrial cancer.

[0059] Beneficial technical effects of the present invention: The present invention provides a benzothiazolylpyrimidine amine DYRK2 inhibitor, which has a strong inhibitory activity on DYRK2 kinase activity, IC 50 (nM) value can reach 0.1nM-1000nM, preferably IC 50 (nM) values ​​range from 1nM to 100nM, and some compounds have inhibitory activity against DYRK2 IC 50 (nM) value is less than 10nM.

[0060] The following is an explanation and description of the terms of the present invention:

[0061] "Cancer" or "malignancy" refers to any of a variety of diseases characterized by uncontrolled abnormal proliferation of cells, the ability of affected cells to spread locally or via the bloodstream and lymphatic system to other parts of the body (i.e., metastasis), and any of a number of characteristic structural and / or molecular features. "Cancer cell" refers to a cell that is undergoing an early, intermediate, or advanced stage of multi-step neoplastic progression. Cancers include lung cancer, leukemia, breast cancer, prostate cancer, multiple myeloma, liver cancer, stomach cancer, bone cancer, brain cancer, head and neck cancer, bowel cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, or endometrial cancer.

[0062] The compounds and derivatives provided in the present invention can be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, Columbus, OH) nomenclature system.

[0063] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for groups or terms in this document apply to the groups or terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art can give them should be given based on the disclosure and context.

[0064] "Substitution" refers to the replacement of a hydrogen atom in a molecule by another different atom or molecule.

[0065] The minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix C a~b Alkyl refers to any alkyl group containing from "a" to "b" carbon atoms. Thus, for example, "C 1~6 "Alkyl" refers to an alkyl group containing 1 to 6 carbon atoms. 1~8 The term "alkyl" refers to an alkyl group containing 1 to 8 carbon atoms.

[0066] "Alkyl" refers to a saturated hydrocarbon chain with a specified number of member atoms. For example, C1-8 alkyl refers to an alkyl group with 1 to 8 member atoms, and C1-6 alkyl refers to an alkyl group with 1 to 6 member atoms, such as 1 to 4 member atoms, 1 to 3 member atoms. The alkyl group can be straight or branched. Representative branched alkyl groups have one, two or three branches. The alkyl group may be optionally substituted with one or more substituents as defined herein. Alkyl includes methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl, etc. The alkyl group can also be part of other groups, such as C1-C8 alkoxy, C1-C6 alkoxy.

[0067] "Cycloalkyl", "cycloalkane" refers to a saturated or partially saturated cyclic group having carbon atoms and no ring heteroatoms and having a single ring or multiple rings (including fused, combined and). For polycyclic systems with aromatic and non-aromatic rings without ring heteroatoms, when the point of attachment is located at a non-aromatic carbon atom, the term "cycloalkyl" (e.g., 5,6,7,8,-tetrahydronaphthalene-5-yl) is applicable. The term "cycloalkyl" includes cycloalkenyl groups, such as cyclohexenyl. Examples of cycloalkyl groups include, for example, adamantyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclooctyl, cyclopentenyl, and cyclohexenyl, etc. Examples of cycloalkyl groups including polybicycloalkyl ring systems are bicyclohexyl, bicyclopentyl, bicyclooctyl, etc.

[0068] "Alkenyl" refers to a straight or branched chain hydrocarbon group having 2 to 10 carbon atoms, and in some embodiments 2 to 6 carbon atoms or 2 to 4 carbon atoms, and having at least 1 site of vinyl unsaturation (>C=C<). For example, (Ca-Cb)alkenyl refers to an alkenyl group having a to b carbon atoms and is meant to include, for example, ethenyl, propenyl, isopropenyl, 1,3-butadienyl, and the like.

[0069] "Alkynyl" refers to a straight chain monovalent hydrocarbon group or a branched monovalent hydrocarbon group containing at least one triple bond. The term "alkynyl" is also intended to include those hydrocarbon groups having one triple bond and one double bond. For example, C2-C6 alkynyl is intended to include ethynyl, propynyl, etc.

[0070] "Halogen" is fluorine, chlorine, bromine or iodine.

[0071] "Haloalkyl" or "haloalkyl" means that the hydrogen atoms in the alkyl group may be replaced by one or more halogen atoms. 1~8 Halogenalkyl refers to an alkyl group containing 1 to 8 carbon atoms in which the hydrogen atoms are replaced by one or more halogen atoms; 1~4 The halogenalkyl group refers to an alkyl group containing 1 to 4 carbon atoms in which hydrogen atoms are substituted by one or more halogen atoms.

[0072] "Heterocycle", "heterocycloalkyl", "heterocycloalkane" refer to a saturated ring or a non-aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom, an oxygen atom, or a sulfur atom; the term "heterocyclyl" is a heterocycloalkyl, which means a monocyclic or condensed ring containing one or more heteroatoms of N, O or S. The term "C4-C8 heterocyclyl" refers to a heterocyclyl containing 4 to 8 carbon atoms in its ring. C4-C8 heterocyclyl includes, but is not limited to, piperazinyl, morpholino, piperidino, pyrrolidinyl, and the like.

[0073] "Aromatic heterocycle" refers to an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to a nitrogen atom, an oxygen atom, or a sulfur atom; the term "heteroaryl" refers to a monocyclic or fused ring group containing one, two, three, or four ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and having a completely conjugated π electron system. The term "C3-C10 heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms in its ring. C3-C10 heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyrimidine, and pyridine.

[0074] The term "C6-C 10 "Aryl" refers to an all-carbon monocyclic or fused polycyclic group of 6 to 10 carbon atoms, with a completely conjugated π electron system. Typical examples include, but are not limited to, benzene ring groups and naphthyl ring groups.

[0075] The term "pharmaceutically acceptable" means that a carrier, vehicle, diluent, excipient, and / or formed salt is generally chemically or physically compatible with the other ingredients that constitute a pharmaceutical dosage form and physiologically compatible with the receptor.

[0076] The pharmaceutical composition of the present invention can be any reusable pharmaceutical preparation form, such as oral, injection, external use, etc., and the oral dosage form includes but is not limited to tablets, capsules, oral liquids, granules, pills, suspensions, injections selected from water injections and powder injections, and external preparations selected from patches and ointments. All preparations can be prepared according to conventional pharmaceutics techniques, such as using the compound of the present invention, or any one of its stereoisomers, or its pharmaceutically acceptable salt as a pharmaceutically active ingredient, adding a pharmaceutically acceptable carrier if necessary, to prepare the above-mentioned pharmaceutical dosage form suitable for taking, wherein the pharmaceutically active ingredient per unit dose can be 0.1 mg-1000 mg, such as each tablet containing 0.1 mg-1000 mg, preferably 5-500 mg, of the pharmaceutically active ingredient.

[0077] The terms "salt", "pharmaceutically acceptable salt", "pharmaceutically acceptable salt" refer to acidic and / or basic salts formed by the above-mentioned compounds or their stereoisomers with inorganic and / or organic acids and bases, and also include zwitterionic salts (inner salts), and also include quaternary ammonium salts, such as alkylammonium salts. These salts can be directly obtained in the final separation and purification of the compound. It can also be obtained by mixing the above-mentioned compound, or its stereoisomer, with a certain amount of acid or base appropriately (for example, equivalent amount). These salts may form a precipitate in the solution and be collected by filtration, or be recovered after the solvent is evaporated, or be obtained by freeze-drying after reaction in an aqueous medium. The salt described in the present invention can be a hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate of the compound. BRIEF DESCRIPTION OF THE DRAWINGS

[0078] Figure 1 The compound of Example 20 of the present invention significantly inhibits the proliferation of prostate cancer DU145 and 22Rv1 cells;

[0079] Figure 2 is the change in animal body weight and organ weight in the acute toxicity experiment in Example 20 of the present invention;

[0080] Figure 3 The compound of Example 40 of the present invention significantly inhibits the proliferation of prostate cancer DU145 and 22Rv1 cells;

[0081] Figure 4 is the change in animal body weight and organ weight in the acute toxicity experiment of Example 40 of the present invention;

[0082] Figure 5 This is the in vivo activity test of the compound of Example 20 of the present invention against prostate cancer;

[0083] Figure 6This is an in vivo anti-prostate cancer activity test of the compound in Example 40 of the present invention. DETAILED DESCRIPTION

[0084] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified. The present application is described in detail below in conjunction with specific embodiments.

[0085] Intermediate Preparation Example 1: Synthesis of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole (A-1)

[0086]

[0087] 5-Bromobenzothiazole (0.43 g, 2.0 mmol) was dissolved in 1,4-dioxane (10 mL), and then pinacol borate (0.53 g, 2.1 mmol), Pd(dppf)Cl2 (22 mg, 0.06 mmol), potassium acetate (0.59 g, 6.0 mmol) were added, argon was replaced three times, heated to 100 ° C, and reacted for 8 hours. Cool, filter, concentrate, and quickly purify on a silica gel column to obtain the compound 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolpentane-2-yl)benzothiazole (0.44 g, 86% yield). 1 HNMR (400MHz, CDCl3) δ9.00(s,1H),8.60–8.59(m,1H),7.97(dd,J=8.0,0.7Hz,1H),7.86(dd,J=8.0,1.0Hz,1H),1.39(s,12H).

[0088] Intermediate Preparation Example 2: Synthesis of 5-(2-chloro-5-methylpyrimidin-4-yl)benzothiazole (A-2)

[0089]

[0090] Weigh the compound 2,4-dichloro-5-methylpyrimidine (0.28 g, 1.4 mmol) and add it to a 250 mL three-necked flask, then add Pd(PPh3)2Cl2 (21 mg, 0.03 mmol), sodium carbonate (0.27 g, 2.5 mmol), ethylene glycol dimethyl ether (10 mL) and water (0.25 mL), replace the argon three times, and heat to 80 ° C. Compound 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole A-1 (0.26 g, 1.0 mmol) was dissolved in ethylene glycol dimethyl ether (5 mL) and added dropwise to the three-necked flask, and reacted for 16 hours. Cool, filter, concentrate, and quickly purify on a silica gel column to obtain compound 5-(2-chloro-5-methylpyrimidin-4-yl)benzothiazole A-2 (0.21 g, 80% yield). 1 HNMR (300MHz, CDCl3) δ9.10(s,1H),8.56(s,1H),8.39(dd,J=1.7,0.6Hz,1H),8.11(dd,J=8.4,0.6Hz,1H),7.78(dd,J=8.4,1.7Hz,1H),2.47(s,3H).

[0091] Intermediate Preparation Example 3: Synthesis of 5-(2-chloro-5-methoxypyrimidin-4-yl)benzothiazole (A-3)

[0092]

[0093] The yield of the synthetic method of reference compound A-2 was 78%. 1 HNMR (300MHz, CDCl3) δ9.07(s,1H),8.98(dd,J=1.7,0.6Hz,1H),8.37(s,1H),8.26(dd,J=8.6,1.7Hz,1H),8.07(dd,J=8.6,0.6Hz,1H),4.05(s,3H).

[0094] Intermediate Preparation Example 4: Synthesis of 5-(2-chloropyrimidin-4-yl)benzothiazole (A-4)

[0095]

[0096] The yield of the synthetic method of reference compound A-2 was 73%. 1 HNMR (300MHz, CDCl3) δ9.11 (s, 1H), 8.83 (d, J = 1.7Hz, 1H), 8.71 (d, J = 5.3Hz, 1 H), 8.29 (dd, J = 8.5, 1.7Hz, 1H), 8.12 (d, J = 8.5Hz, 1H), 7.79 (d, J = 5.3Hz, 1H).

[0097] Intermediate Preparation Example 5: Synthesis of 5-(2-chloro-5-fluoropyrimidin-4-yl)benzothiazole (A-5)

[0098]

[0099] The yield of the synthetic method of reference compound A-2 was 78%. 1 HNMR (400MHz, CDCl3) δ9.11 (s, 1H), 8.94 (s, 1H), 8.58 (d, J = 3.1Hz, 1H), 8.29 (dd, J = 8.5, 1.7Hz, 1H), 8.13 (d, J = 8.5Hz, 1H).

[0100] Intermediate Preparation Example 6: Synthesis of 6-bromo-N,N-dimethylbenzothiazol-2-amine (A-6)

[0101]

[0102] 5-Bromo-2-chlorobenzothiazole (1 g, 4 mmol) and dimethylamine (0.72 g, 16 mmol) were dissolved in THF (15 mL), heated to 75 °C and refluxed, reacted for 6 h, and purified by flash silica gel column to obtain compound 5-bromo-N,N-dimethylbenzothiazole-2-amine A-6 (0.84 g, 82% yield). 1 HNMR (400MHz, CDCl3) δ7.69(d,J=1.9Hz,1H),7.42(d,J=8.3Hz,1H),7.14(dd,J=8.3,1.9Hz,1H),3.19(s,6H).

[0103] Intermediate Preparation Example 7: Synthesis of N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole (A-7)

[0104]

[0105] The yield of the synthetic method of reference compound A-1 was 75%. 1 H NMR (400MHz, CDCl3) δ8.03–8.02(m,1H),7.60(dd,J=7.9,0.6Hz,1H),7.48(dd,J=7.9,1.1Hz,1H),3.20(s,6H),1.34(s,12H).

[0106] Intermediate Preparation Example 8: Synthesis of 5-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-dimethylbenzothiazol-2-amine (A-8)

[0107]

[0108] The yield of the synthetic method of reference compound A-2 was 74%. 1 H NMR (400MHz, CDCl3) δ8.49(d,J=3.3Hz,1H),8.36–8.34(m,1H),7.90–7.87(m,1H),7.72(d,J=8.4Hz,1H),3.24(s,6H).

[0109] Intermediate Preparation Example 9: Synthesis of 5-bromo-N,N-diethylbenzothiazol-2-amine (A-9)

[0110]

[0111] 5-Bromo-2-chlorobenzothiazole (2.49 g, 10 mmol) and diethylamine (2.93 g, 40 mmol) were dissolved in THF (100 mL), heated to 75 °C and refluxed, reacted for 12 h, and purified by rapid silica gel column to obtain compound 5-bromo-N,N-diethylbenzothiazole-2-amine A-9 (2.37 g, 83% yield). 1 H NMR (400MHz, CDCl3) δ7.66(d,J=1.9Hz,1H),7.39(d,J=8.3Hz,1H),7.12(dd,J=8.3,1.9Hz,1H),3.55(q,J=7.1Hz,4H),1.27(t,J=7.1Hz,6H).

[0112] Intermediate Preparation Example 10: Synthesis of N,N-diethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole (A-10)

[0113]

[0114] The yield of the synthetic method of reference compound A-1 was 72%. 1 H NMR (400MHz, CDCl3) δ8.01–8.00(m,1H),7.58(d,J=7.8Hz,1H),7.45(dd,J=7.8,1.1Hz,1H),3.56(q,J=7.0Hz,4H),1.34(s,12H),1.28(t,J=7.0Hz,6H).

[0115] Intermediate Preparation Example 11: Synthesis of 5-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-diethylbenzothiazol-2-amine (A-11)

[0116]

[0117] The yield of the synthetic method of reference compound A-2 was 72%. 1 H NMR (400MHz, CDCl3) δ8.47(d,J=3.3Hz,1H),8.32(s,1H),7.87–7.84(m,1H),7.69(d,J=8.4Hz,1H),3.60(q,J=7.2Hz,4H),1.31(t,J=7.2Hz,6H).

[0118] Intermediate Preparation Example 12: Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-dimethylbenzothiazol-2-amine (A-12)

[0119] Step 1: Synthesis of 6-bromo-N,N-dimethylbenzothiazol-2-amine (A-12-1)

[0120]

[0121] Weigh 4-bromo-2-iodoaniline (0.60 g, 2.0 mmol), sodium dimethyldithiocarbamate dihydrate (0.72 g, 4.0 mmol), copper acetate (0.36 g, 2.0 mmol) and potassium carbonate (0.55 g, 4.0 mmol) and dissolve in DMF (10 mL), heat to 120 ° C, and react for 6 hours. Cool, filter, concentrate, and purify with a rapid silica gel column to obtain compound 6-bromo-N, N-dimethylbenzothiazol-2-amine (A-12-1) (0.44 g, 85% yield). 1 H NMR (400MHz, CDCl3) δ7.69 (d, J = 1.9Hz, 1H), 7.41–7.35 (m, 2H), 3.20 (s, 6H).

[0122] Step 2, Synthesis of N,N-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole-2-amine (A-12-2)

[0123]

[0124] Intermediate A-12-1 (0.51 g, 2.0 mmol) was dissolved in DMF (10 mL), and then pinacol borate (0.53 g, 2.1 mmol), Pd(dppf)Cl2 (22 mg, 0.06 mmol), potassium acetate (0.59 g, 6.0 mmol) were added, argon was replaced three times, heated to 80 ° C, and reacted for 24 hours. Cool, filter, concentrate, and quickly purify on a silica gel column to obtain compound N, N-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolpentane-2-yl)benzothiazole-2-amine A-12-2 (0.54 g, 88% yield). MS (M+H) +:found,305.3.

[0125] Step 3, Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-dimethylbenzothiazol-2-amine (A-12)

[0126]

[0127] Weigh the compound 2,4-dichloro-5-fluoropyrimidine (0.23 g, 1.4 mmol) and add it to a 250 mL three-necked flask, then add Pd(PPh3)2Cl2 (21 mg, 0.03 mmol), sodium carbonate (0.27 g, 2.5 mmol), ethylene glycol dimethyl ether (10 mL) and H2O (0.25 mL), replace the argon three times, and heat to 80°C. N,N-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole-2-amine A-12-2 (0.3 g, 1.0 mmol) was dissolved in ethylene glycol dimethyl ether (5 mL), added dropwise to the three-necked flask, and reacted for 16 hours. The mixture was cooled, filtered, concentrated, and purified by flash silica gel column to obtain compound 6-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-dimethylbenzothiazol-2-amine A-12 (0.25 g, 80% yield). 1 H NMR (400MHz, CDCl3) δ8.49 (d, J = 1.9 Hz, 1H), 8.45 (d, J = 3.6 Hz, 1H), 8.17–8.14 (m, 1H), 7.62 (d, J = 8.7 Hz, 1H), 3.27 (s, 6H).

[0128] Intermediate Preparation Example 13: Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-diethylbenzothiazol-2-amine (A-13)

[0129] Step 1, Synthesis of 6-bromo-N,N-diethylbenzothiazol-2-amine (A-13-1)

[0130]

[0131] Weigh 4-bromo-2-iodoaniline (0.60 g, 2.0 mmol), sodium diethyldithiocarbamate trihydrate (0.90 g, 4.0 mmol), copper acetate (0.36 g, 2.0 mmol) and potassium carbonate (0.55 g, 4.0 mmol) and dissolve in DMF (10 mL), heat to 120 ° C, and react for 6 hours. Cool, filter, concentrate, and quickly purify on a silica gel column to obtain compound 6-bromo-N, N-dimethylbenzothiazole-2-amine (A-13-1) (0.46 g, 80% yield). MS (M+H) + :found,285.1.

[0132] Step 2, Synthesis of N,N-diethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole-2-amine (A-13-2)

[0133]

[0134] Refer to the synthesis method of compound (A-12-2), yield 90%. MS (M+H) + :found,333.3.

[0135] Step 3, Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-N,N-diethylbenzothiazole-2-amine (A-13)

[0136]

[0137] The yield of the compound (A-12) was 82%. 1 H NMR (300MHz, CDCl3) δ 8.44 (dd, J = 8.8, 2.7Hz, 2H), 8.13 (d, J = 8.6Hz, 1H), 7.58 (d, J = 8.7Hz, 1H), 3.61 (q, J = 7.2Hz, 4H), 1.32 (t, J = 7.2Hz, 6H).

[0138] Intermediate Preparation Example 14: Synthesis of (6-aminopyridin-3-yl)(4-ethylpiperazine-1-yl)methanone (B-1)

[0139]

[0140] Weigh 6-aminonicotinic acid (0.69 g, 5 mmol), N,N'-carbonyldiimidazole (1.62 g, 10 mmol) and dissolve in DMF (30 mL), react at 70°C for 10 minutes, stir at room temperature for another hour, add N-ethylpiperazine (0.69 g, 6 mmol), react at room temperature overnight, concentrate, and quickly purify by silica gel column to obtain compound B-1 (0.97 g, yield 83%). 1 H NMR (400MHz, CDCl3) δ8.18 (dd, J=2.4, 0.8Hz, 1H), 7.54 (dd, J=8.5, 2.4Hz, 1H), 6.49 (dd, J=8.5,0.9Hz,1H),4.95(s,2H),3.67(brs,4H),2.48–2.43(m,6H),1.10(t,J=7.2Hz,3H).

[0141] Intermediate Preparation Example 15: Synthesis of tert-butyl 4-(6-aminonicotinyl)piperazine-1-carboxylate (B-2)

[0142]

[0143] The yield of the synthetic method of reference compound (B-1) was 85%. 1 H NMR (400MHz, CDCl3) δ8.19 (dd, J=2.3, 0.8Hz, 1H), 7.57 (dd, J=8.5, 2.3Hz, 1H), 6.51 (d d,J=8.5,0.8Hz,1H),4.70(s,2H),3.62–3.58(m,4H),3.48–3.45(m,4H),1.48(s,9H).

[0144] Intermediate Preparation Example 16: Synthesis of 1-(4-(6-aminonicotinyl)piperazin-1-yl)ethyl-1-one (B-3)

[0145]

[0146] The yield of the synthetic method of reference compound (B-1) was 79%. 1 H NMR (400MHz, CDCl3) δ8.20(dd,J=2.3,0.8Hz,1H),7.56(dd,J=8.5,2.3Hz,1H),6.52(dd,J=8.5,0.8Hz,1H),4.88(s,2H),3.70–3.58(m,8H),2.14(s,3H).

[0147] Intermediate Preparation Example 17: Synthesis of 4-(6-aminonicotinyl)piperazin-1-yl)(cyclopropyl)methanone (B-4)

[0148]

[0149] The yield of the synthetic method of reference compound (B-1) was 79%. 1 H NMR (400MHz, CDCl3) δ8.19 (dd, J=2.4, 0.8Hz, 1H), 7.55 (dd, J=8.6, 2.4Hz, 1H), 6.52 (dd, J=8.6, 0. 8Hz,1H),5.12(s,2H),3.74–3.62(m,8H),1.77–1.73(m,1H),1.02–0.99(m,2H),0.83–0.75(m,2H).

[0150] Intermediate Preparation Example 18: Synthesis of (6-aminopyridin-3-yl)(4-arylpiperazin-1-yl)methanone (B-5)

[0151]

[0152] The yield of the synthetic method of reference compound (B-1) was 73%. 1 H NMR(400MHz, CDCl3)δ8.22(dd,J=2.3,0.8Hz,1H),7.58(dd,J=8.5,2.3Hz,1H),7.30–7.27(m,2H),6.95–6.9 2(m,2H),6.90–6.85(m,1H),6.52(dd,J=8.5,0.8Hz,1H),4.86(s,2H),3.81–3.79(m,4H),3.22–3.19(m,4H).

[0153] Intermediate Preparation Example 19: Synthesis of Ethyl 4-(6-aminonicotinyl)piperazine-1-carboxylate (B-6)

[0154]

[0155] The yield of the synthetic method of reference compound (B-1) was 73%. 1 H NMR (400MHz, CDCl3) δ8.18(s,1H),7.53(d,J=8.6Hz,1H),6.52(d,J=8.6Hz, 1H),5.13(s,2H),4.18–4.13(m,2H),3.63–3.44(m,8H),1.30–1.25(m,3H).

[0156] Intermediate Preparation Example 20: Synthesis of (5-aminopyridin-2-yl)(4-ethylpiperazine-1-yl)methanone (B-7)

[0157]

[0158] Weigh 5-amino-2-pyridinecarboxylic acid (0.69 g, 5 mmol), N-ethylpiperazine (0.69 g, 6 mmol), HATU (2.85 g, 7.5 mmol), N-methylmorpholine (1.26 g, 12.5 mmol), dissolve in dichloromethane (30 mL), stir at room temperature for 8 hours, concentrate, and purify by rapid silica gel column to obtain compound B-7 (0.89 g, yield 76%). The yield is 82%. MS (M+H) + :found,235.4

[0159] Intermediate Preparation Example 21: Synthesis of (5-aminopyridin-2-yl)(4-isopropylpiperazin-1-yl)methanone (B-8)

[0160]

[0161] The yield of the reference compound (B-7) was 73%. MS (M+H) + :found,249.4

[0162] Intermediate Preparation Example 22: Synthesis of tert-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (B-9)

[0163]

[0164] The yield of the reference compound (B-7) was 75%. MS (M+H) + :found,307.4

[0165] Intermediate Preparation Example 23: Synthesis of (2-aminopyrimidin-5-yl)(4-ethylpiperazine-1-yl)methanone (B-10)

[0166]

[0167] Weigh 2-aminopyrimidine-5-carboxylic acid (0.60 g, 5 mmol), EDCI (2.88 g, 15 mmol), HOBt (1.01 g, 7.5 mmol), and triethylamine (2.53 g, 25 mmol) and dissolve in DMF (30 mL). Stir at room temperature for half an hour, add N-ethylpiperazine (0.69 g, 6 mmol), and stir for another 8 hours. Concentrate and purify quickly on a silica gel column to obtain compound B-10 (0.84 g, yield 71%). 1 H NMR (300MHz, CDCl3) δ8.41 (s, 2H), 5.55 (s, 2H), 3.70–3.58 (m, 4H), 2.48–2.41 (m, 6H), 1.09 (t, J = 7.2Hz, 3H).

[0168] Intermediate Preparation Example 24: Synthesis of tert-butyl 4-(2-aminopyrimidine-5-carbonyl)piperazine-1-carboxylate (B-11)

[0169]

[0170] The yield of the reference compound (B-10) was 73%. MS (M+Na) + :found,330.4

[0171] Intermediate Preparation Example 25: Synthesis of 5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-amine (B-12)

[0172]

[0173] 2-Amino-5-formylpyridine (2.34 g, 10 mmol) and N-ethylpiperazine (1.37 g, 12 mmol) were dissolved in 1,2-dichloroethane (50 mL), stirred at room temperature for 2 hours, then sodium triacetylborohydride (3.18 g, 15 mmol) was added, and stirred at room temperature for 8 hours. Water was added to quench, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and column chromatography was performed to obtain compound B-12 (1.81 g, yield 82%). 1 H NMR(400MHz,Chloroform-d)δ7.91(d,J=2.3Hz,1H),7.43(dd,J=8.4,2.3Hz,1H),6.48(d,J=8 .4Hz,1H),4.71(s,2H),3.38(s,2H),3.06(brs,4H),2.52–2.44(m,6H),1.10(t,J=7.2Hz,3H).

[0174] Intermediate Preparation Example 26: Synthesis of 5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-amine (B-13)

[0175]

[0176] The yield of the reference compound (B-12) was 79%. MS (M+H) + :found,235.2.

[0177] Intermediate Preparation Example 27: Synthesis of tert-butyl 4-((6-aminopyridin-3-yl)methyl)piperazine-1-carboxylate (B-14)

[0178]

[0179] The yield of the reference compound (B-12) was 86%. MS (M+H) + :found,293.3.

[0180] Intermediate Preparation Example 28: Synthesis of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole (C-1)

[0181]

[0182] The yield of the synthetic method of reference compound (A-1) was 90%. 1 H NMR (400MHz, CDCl3) δ9.05 (s, 1H), 8.45 (d, J = 1.1Hz, 1H), 8.13 (d, J = 8.2Hz, 1H), 7.94 (dd, J = 8.2, 1.1Hz, 1H), 1.38 (s, 12H).

[0183] Intermediate Preparation Example 29: Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)benzothiazole (C-2)

[0184]

[0185] The yield of the synthetic method of reference compound (A-2) was 82%. 1 H NMR (400MHz, CDCl3) δ9.17 (s, 1H), 8.85 (d, J = 1.7Hz, 1H), 8.58 (d, J = 3.1Hz, 1H), 8.35–8.26 (m, 2H).

[0186] Intermediate Preparation Example 30: Synthesis of 6-(2-chloro-5-methylpyrimidin-4-yl)benzothiazole (C-3)

[0187]

[0188] The yield of the synthetic method of reference compound (A-2) was 77%. 1 H NMR (400MHz, DMSO) δ9.55 (s, 1H), 8.76 (s, 1H), 8.57 (d, J = 1.7Hz, 1H), 8.23 ​​(d, J = 8.5Hz, 1H), 7.87 (dd, J = 8.5, 1.7Hz, 1H), 2.41 (s, 3H).

[0189] Intermediate Preparation Example 31: Synthesis of 6-(2-chloro-5-methoxypyrimidin-4-yl)benzothiazole (C-4)

[0190]

[0191] The yield of the synthetic method of reference compound (A-2) was 81%. 1 H NMR (400MHz, DMSO) δ9.55(s,1H),8.91–8.90(m,1H),8.73(s,1H),8.25–8.20(m,2H),4.06(s,3H).

[0192] Intermediate Preparation Example 32: Synthesis of 6-(2-chloropyrimidin-4-yl)benzothiazole (C-5)

[0193]

[0194] The yield of the synthetic method of reference compound (A-2) was 81%. 1H NMR (400MHz, CDCl3) δ9.14 (s, 1H), 8.85 (d, J = 1.7Hz, 1H), 8.69 (d, J = 5.3Hz, 1H), 8.27–8.17 (m, 2H), 7.75 (d, J = 5.3Hz, 1H).

[0195] Intermediate Preparation Example 33: Synthesis of 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole (C-6)

[0196]

[0197] The yield of the synthetic method of reference compound (A-1) was 90%. 1 H NMR (400MHz, CDCl3) δ8.31–8.30(m,1H),7.94–7.85(m,2H),2.84(s,3H),1.36(s,12H).

[0198] Intermediate Preparation Example 34: Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-2-methylbenzothiazole (C-7)

[0199]

[0200] The yield of the synthetic method of reference compound (A-2) was 84%. 1 H NMR (300MHz, DMSO) δ9.00 (d, J = 3.4Hz, 1H), 8.80–8.79 (m, 1H), 8.17–8.08 (m, 2H), 2.87 (s, 3H).

[0201] Intermediate Preparation Example 35: Synthesis of 6-bromo-N-cyclopentylbenzothiazol-2-amine (C-8)

[0202]

[0203] 6-Bromo-2-chlorobenzothiazole (0.5 g, 2 mmol), cyclopentylamine (0.19 g, 2.2 mmol), and DIPEA (0.39 g, 3 mmol) were dissolved in DMSO (10 mL), and the argon gas was replaced three times. The mixture was heated to 80 ° C and reacted for 12 h. The compound 6-bromo-N-cyclopentylbenzothiazole-2-amine C-8 (0.53 g, 90% yield) was obtained by rapid silica gel column purification. 1H NMR (400MHz, CDCl3) δ7.68 (d, J = 1.7Hz, 1H), 7.38–7.33 (m, 2H), 6.28 (s, 1H), 3.98–3.93 (m, 1H), 2.14–2.04 (m, 2H), 1.72–1.54 (m, 6H).

[0204] Intermediate Preparation Example 36: Synthesis of N-cyclopentyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzothiazole-2-amine (C-9)

[0205]

[0206] The yield of the synthetic method of reference compound (A-1) was 88%. 1 H NMR (400MHz, CDCl3) δ8.05 (d, J=1.2Hz, 1H), 7.73 (dd, J=8.0, 1.2Hz, 1H), 7.49 (d, J=8.0Hz ,1H),5.74(s,1H),4.03–4.00(m,1H),2.13–2.07(m,2H),1.76–1.56(m,6H),1.35(s,12H).

[0207] Intermediate Preparation Example 37: Synthesis of 6-(2-chloro-5-fluoropyrimidin-4-yl)-2-methylbenzothiazole (C-10)

[0208]

[0209] The yield of the synthetic method of reference compound (A-2) was 83%. 1 H NMR (400MHz, CDCl3) δ8.49 (d, J=

[0210] 1.9Hz,1H),8.46(d,J=3.5Hz,1H),8.17–8.14(m,1H),7.58(d,J=8.6Hz,1 H),5.88(s,1H),4.13–4.07(m,1H),2.19–2.11(m,2H),1.77–1.61(m,6H).

[0211] Example 1: Synthesis of 4-(Benzothiazol-5-yl)-N-(5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)-5-methylpyrimidin-2-amine (P-1)

[0212]

[0213] Compound A-2 (261.7 mg, 1.0 mmol) and B-13 (281.2 mg, 1.2 mmol) were dissolved in dioxane (10 mL), and then Pd2(dba)3 (45.8 mg, 0.05 mmol), BINAP (62.3 mg, 0.1 mmol), cesium carbonate (651.6 mg,

[0214] 2.0 mmol), argon was replaced three times, heated to 100°C, and reacted for 12 hours. The mixture was cooled, filtered, concentrated, and column chromatographed to obtain compound P-1 (193.0 mg, 42% yield) as a white solid. 1 H NMR(400MHz, CDCl3)δ9.10(s,1H),8.45–8.43(m,3H),8.21(d,J=2.3Hz,1H),8.12(d,J=8.4Hz,1H),8.04(s,1H), 7.78(dd,J=8.4,1.6Hz,1H),7.61–7.58(m,1H),3.55(s,2H),3.38–2.89(m,9H),2.37(s,3H),1.44–1.40(m,6H).

[0215] Example 2: Synthesis of 4-(Benzothiazol-5-yl)-5-methyl-N-(5-(piperazine-1-methylene)piperidin-2-yl)pyrimidin-2-amine hydrochloride (P-2)

[0216] Step 1: Synthesis of intermediate P-2-1

[0217]

[0218] The synthesis of intermediate P-2-1 was carried out according to the synthesis method of Example 1, with a yield of 45%, and the product was a white solid. 1 H NMR(400MHz, CDCl3)δ9.10(s,1H),8.43–8.42(m,3H),8.19(d,J=2.3Hz,1H),8.11(dd,J=8.3,0.6Hz,1H),7.98(s,1H),7.79 (dd,J=8.3,1.7Hz,1H),7.66–7.64(m,1H),3.46(s,2H),3.43–3.40(m,4H),2.39–2.37(m,7H),1.45(s,9H).HRMS(ESI)calcd 518.2333; found,518.2326.

[0219] Step 2: Synthesis of final product P-2

[0220]

[0221] Intermediate P-2-1 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to give compound P-2 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ11.85(s,1H),9.86(s,2H),9.54(s,1H),8.73(d,J=0.8Hz,1H),8.64(d,J=2.2Hz,1H),8.47(d,J=1.6Hz,1H),8. 40(dd,J=10.3,7.6Hz,2H),7.91(d,J=8.9Hz,1H),7.88–7.85(m,1H),4.47(s,2H),3.50–3.34(m,8H),2.43(s,3H).HRMS(ESI)calcd 418.1808; found,418.1807.

[0222] Example 3: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-methylpyrimidin-2-yl)amine)pyridin-3-yl)(4-ethylpiperazine-1-yl)methanone (P-3)

[0223]

[0224] The synthetic method of reference example 1 has a yield of 37% and is a white solid. 1 H NMR (400MHz, CDCl3) δ9.19(s,1H),9.10(s,1H),8.56–8.53(m,3H),8.43(d,J=1.6Hz,1H),8.12(d,J=8.3Hz,1H) ,7.80–7.75(m,2H),3.77–3.60(m,4H),2.48–2.42(m,6H),2.36(s,3H),1.10(t,J=7.2Hz,3H).HRMS(ESI):calcd 460.1914; found,460.1904.

[0225] Example 4: Synthesis of tert-butyl 4-(6-((4-(benzothiazol-5-yl)-5-methylpyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-4)

[0226]

[0227] The synthetic method of reference example 1 has a yield of 38% and is a white solid. 1H NMR(400MHz, CDCl3)δ9.10(s,1H),8.85(s,1H),8.56(dd,J=8.8,0.8Hz,1H),8.51–8.50(m,1H),8.48(dd,J=2.4,0.8Hz,1H),8 .43(d,J=1.6Hz,1H),8.12(d,J=8.4Hz,1H),7.80–7.74(m,2H),3.66–3.44(m,8H),2.38(s,3H),1.48(s,9H).HRMS(ESI)calcd 532.2125; found,532.2124.

[0228] Example 5: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-methylpyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-5)

[0229]

[0230] P-4 (100 mg) was dissolved in dichloromethane (15 mL), and 3 mL of 2M EA-HCl solution was added dropwise. The mixture was stirred for 8 hours and concentrated to obtain compound P-5 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ12.03(s,1H),9.80(s,2H),9.55(s,1H),8.75(s,1H),8.59(d,J=2.0Hz,1H),8.47(d,J=1.5Hz,1H),8.39(d,J=8.3Hz,1H),8. 24(dd,J=8.9,2.0Hz,1H),7.93(d,J=8.9Hz,1H),7.88(dd,J=8.3,1.6Hz,1H),3.83–3.74(m,4H),3.18–3.16(m,4H),2.43(s,3H).HRMS(ESI)calcd 432.1601; found,432.1595.

[0231] Example 6: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-methoxypyrimidin-2-yl)amine)pyridin-3-yl)(piperazine-1-yl)methanone hydrochloride (P-6)

[0232] Step 1: Synthesis of intermediate P-6-1

[0233]

[0234] The synthesis of intermediate P-6-1 was carried out according to the synthesis method of Example 1, with a yield of 41%, and the product was a white solid. 1H NMR (400MHz, CDCl3) δ9.08 (s, 1H), 8.96 (dd, J = 1.7, 0.6Hz, 1H), 8.52–8.50 (m, 1H),8.40(dd,J=2.3,0.8Hz,1H),8.37(s,1H),8.25(dd,J=8.5,1.7Hz,1H),8.1 7(s,1H),8.09(dd,J=8.5,0.6Hz,1H),7.80(dd,J=8.7,2.4Hz,1H),3.98(s,3H) ,3.66–3.47(m,8H),1.48(s,9H).HRMS(ESI)calcd548.2074; found,548.2072.

[0235] Step 2: Synthesis of the final product P-6

[0236]

[0237] The intermediate P-6-1 (100 mg) was dissolved in dichloromethane (15 mL), and 3 mL of 2M EA-HCl solution was added dropwise. The mixture was stirred for 8 hours and concentrated to obtain compound P-6 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ11.93(s,1H),9.75(s,2H),9.53(s,1H),8.83(d,J=1.5Hz,1H),8.66(s,1H),8.56–8.55(m,1H),8.37(d,J=8. 5Hz,1H),8.23(dd,J=8.3,1.7Hz,2H),7.94(d,J=8.9Hz,1H),4.07(s,3H),3.82–3.76(m,4H),3.20–3.16(m,4H).HRMS(ESI)calcd 448.1550; found,448.1554.

[0238] Example 7: Synthesis of 4-(Benzothiazol-5-yl)-5-methoxy-N-(5-(piperazin-1-ylmethyl)pyridin-2-yl)pyrimidin-2-amine hydrochloride (P-7)

[0239]

[0240] Step 1: Synthesis of intermediate P-7-1: Refer to the synthesis method of Example 1, the yield is 45%, white solid. 1HNMR (400MHz, CDCl3) δ9.07 (s, 1H), 8.97 (dd, J = 1.6, 0.6Hz, 1H), 8.41 (d, J = 8 .5Hz,1H),8.34(s,1H),8.26(dd,J=8.5,1.6Hz,1H),8.20–8.19(m,1H),8.08 (dd,J=8.5,0.6Hz,1H),7.93(s,1H),7.68(d,J=8.6Hz,1H),3.96(s,3H),3.4 8(s,2H),3.45–3.41(m,4H),2.42–2.38(m,4H),1.45(s,9H).HRMS(ESI)calcd 534.2282; found,534.2277.

[0241] Step 2: Dissolve the intermediate P-7-1 (100 mg) in dichloromethane (15 mL), add 3 mL of 2M EA-HCl solution dropwise, stir for 8 hours, and concentrate to obtain compound P-7 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ12.26(s,1H),10.13(s,2H),9.53(s,1H),8.83(d,J=1.6Hz,1H),8.70(d,J=2.1Hz,1H),8.66(s,1H),8.54(dd,J=9.1,2.1H z,1H),8.37(d,J=8.5Hz,1H),8.23(dd,J=8.5,1.7Hz,1H),7.85(d,J=9.1Hz,1H),4.57(s,2H),4.08(s,3H),3.55–3.44(m,8H).HRMS(ESI)forC 24 H 24 FN7O2S(M+H) + :calcd 434.1758; found,434.1750.

[0242] Example 8: Synthesis of 4-(Benzothiazol-5-yl)-N-(5-(piperazine-1-methylene)pyridin-2-yl)pyrimidin-2-amine hydrochloride (P-8)

[0243]

[0244] Step 1: Synthesis of intermediate P-8-1: Refer to the synthesis method of Example 1, the yield is 47%, white solid. 1HNMR(400MHz, CDCl3)δ9.10(s,1H),8.85(d,J=1.7Hz,1H),8.60(d,J=5.2Hz,1H),8.53(d,J=8.5Hz,1H),8.25–8.21(m,2H),8.15(s,1H),8.11(d,J =8.4Hz,1H),7.75(dd,J=9.0,2.2Hz,1H),7.35(d,J=5.2Hz,1H),3.50(s,2H),3.46–3.42(m,4H),2.43–2.39(m,4H),1.46(s,9H).HRMS(ESI)calcd 504.2176; found,504.2159.

[0245] Step 2: Dissolve the intermediate P-8-1 (100 mg) in dichloromethane (15 mL), add 3 mL of 2M EA-HCl solution dropwise, stir for 8 hours, and concentrate to obtain compound P-8 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ11.79(s,1H),9.88(s,2H),9.55(s,1H),8.99(d,J=1.6Hz,1H),8.82(d,J=5.5Hz,1H),8 .67(d,J=2.2Hz,1H),8.44–8.36(m,3H),8.04–8.01(m,2H),4.50(s,2H),3.51–3.43(m,8H).HRMS(ESI)calcd 404.1652; found,404.1650.

[0246] Example 9: Synthesis of (6-((4-(Benzothiazol-5-yl)pyrimidin-2-yl)amine)pyridin-3-yl)(4-ethylpiperazin-1-yl)methanone (P-9)

[0247]

[0248] The synthetic method of reference example 1 has a yield of 36% and is a white solid. 1H NMR (400MHz, CDCl3) δ9.10 (s, 1H), 8.84 (d, J = 1.7Hz, 1H), 8.63 (s, 1H), 8.61 (d, J=2.7Hz,1H),8.45–8.44(m,1H),8.22(dd,J=8.5,1.7Hz,2H),8.12(d,J=8.5Hz, 1H),7.86(dd,J=8.8,2.4Hz,1H),7.41(d,J=5.3Hz,1H),3.86–3.62(m,4H),2.5 6–2.45(m,6H),1.16–1.11(m,3H).HRMS(ESI)calcd446.1758; found,446.1751.

[0249] Example 10: Synthesis of tert-butyl 4-(6-((4-(benzothiazol-5-yl)pyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-10)

[0250]

[0251] The synthetic method of reference example 1 has a yield of 39% and is a white solid. 1 H NMR (300MHz, CDCl3) δ9.11(s,1H),8.84(d,J=1.6Hz,1H),8.66–8.63(m,2H),8.45(dd,J=2.4,0.8Hz,1H),8.34(s,1H),8.23(dd,J=8.4, 1.7Hz,1H),8.12(d,J=8.4Hz,1H),7.86(dd,J=8.7,2.3Hz,1H),7.42(d,J=5.2Hz,1H),3.71–3.48(m,8H),1.48(s,9H).HRMS(ESI)calcd 518.1969; found,518.1970.

[0252] Example 11: Synthesis of (6-((4-(Benzothiazol-5-yl)pyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-11)

[0253]

[0254] The intermediate P-10 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to obtain compound P-11 with a yield of 100%, a light yellow solid. The yield was 100%, a white solid. 1H NMR (400MHz, DMSO) δ11.59(s,1H),9.69(s,2H),9.55(s,1H),8.99(d,J=1.5Hz,1H),8.81(d,J=5.4Hz,1H),8.56(d,J=2.0H z,1H),8.43–8.37(m,2H),8.20–8.11(m,2H),7.99(d,J=5.3Hz,1H),3.82–3.77(m,4H),3.21–3.16(m,4H).HRMS(ESI)calcd 418.1445; found,418.1440.

[0255] Example 12: Synthesis of 4-(Benzothiazol-5-yl)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoropyridin-2-amine (P-12)

[0256]

[0257] The synthetic method of reference example 1 has a yield of 41%, and the product is a white solid. 1 H NMR (300MHz, CDCl3) δ9.10(s,1H),8.93(s,1H),8.54(s,1H),8.51(d,J=3.4Hz,1H),8.41(d,J=8.6Hz,1H),8.29–8.24(m,2H) ,8.12(d,J=8.5Hz,1H),7.73(dd,J=8.7,2.2Hz,1H),3.50(s,2H),2.52–2.39(m,10H),1.09(t,J=7.2Hz,3H).HRMS(ESI)calcd 450.1871; found,450.1869.

[0258] Example 13: Synthesis of 4-(benzothiazol-5-yl)-5-fluoro-N-(5-(piperazine-1-methylene)pyridin-2-yl)pyrimidin-2-amine hydrochloride (P-13)

[0259]

[0260] Step 1: Synthesis of intermediate P-13-1: Refer to the synthesis method of Example 1, the yield is 41%, white solid. 1HNMR (400MHz, CDCl3) δ9.11 (s, 1H), 8.93 (dd, J = 1.7, 0.8Hz, 1H), 8.63 (s, 1H), 8 .51(d,J=3.4Hz,1H),8.43(dd,J=8.6,0.8Hz,1H),8.29(dd,J=2.3,0.8Hz,1H), 8.26–8.23(m,1H),8.12(dd,J=8.5,0.6Hz,1H),7.74(dd,J=8.6,2.3Hz,1H),3. 49(s,2H),3.45–3.43(m,4H),2.42–2.40(m,4H),1.46(s,9H).HRMS(ESI)calcd 522.2082; found, 522.2088.

[0261] Step 2: Dissolve the intermediate P-13-1 (100 mg) in dichloromethane (15 mL), add 3 mL of 2M EA-HCl solution dropwise, stir for 8 hours, and concentrate to obtain compound P-13 with a yield of 100% as a light yellow solid. 1 H NMR(400MHz,DMSO)δ11.72(s,1H),9.94(s,2H),9.57–9.56(m,1H),8.92–8.90(m,1H),8.79(s,1H),8.66(s,1H),8 .44–8.40(m,2H),8.22–8.19(m,1H),8.07(dd,J=8.9,2.7Hz,1H),4.51(s,2H),3.53–3.44(m,8H).HRMS(ESI)calcd 422.1558; found,422.1558.

[0262] Example 14: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(4-ethylpiperazin-1-yl)methanone (P-14)

[0263]

[0264] The synthetic method of reference example 1 has a yield of 33% and is a white solid. 1H NMR (300MHz, CDCl3) δ9.12(s,1H),8.93–8.92(m,1H),8.67(s,1H),8.54–8.48(m,3H),8.26–8.22(m,1H),8.14(d,J=8 .5Hz,1H),7.84(dd,J=8.7,2.4Hz,1H),3.79–3.63(m,4H),2.51–2.44(m,6H),1.12(t,J=7.2Hz,3H).HRMS(ESI)calcd 464.1663; found,464.1662.

[0265] Example 15: Synthesis of 1-(4-(6-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-15)

[0266]

[0267] The synthetic method of reference example 1 has a yield of 38% and is a white solid. 1 H NMR (300MHz, CDCl3) δ9.12(s,1H),9.07(s,1H),8.92(s,1H),8.57–8.54(m,3H),8.26–8. 13(m,2H),7.86(dd,J=8.6,2.4Hz,1H),3.72–3.50(m,8H),2.15(s,3H).HRMS(ESI)calcd 478.1456; found,478.1452.

[0268] Example 16: Synthesis of (4-(6-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)(cyclopropyl)methanone (P-16)

[0269]

[0270] The synthetic method of reference example 1 has a yield of 41% and is a white solid. 1H NMR(300MHz, CDCl3)δ9.12(s,1H),8.93–8.92(m,1H),8.64(s,1H),8.56–8.53(m,2H),8.50(dd,J=2.4,0.8Hz,1H),8.26–8.22(m,1H),8.1 6–8.13(m,1H),7.86(dd,J=8.7,2.3Hz,1H),3.79–3.65(m,8H),1.78–1.72(m,1H),1.06–1.01(m,2H),0.85–0.79(m,2H).HRMS(ESI)calcd 504.1612; found,504.1603.

[0271] Example 17: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(4-phenylpiperazin-1-yl)methanone (P-17)

[0272]

[0273] The synthetic method of reference example 1 has a yield of 39% and is a white solid. 1 H NMR(400MHz, CDCl3)δ9.11(s,1H),8.93(d,J=1.5Hz,1H),8.54–8.51(m,2H),8.48(dd,J=2.4,0.8Hz,1H),8.35(s,1H),8.26–8.23(m,1H),8 .14(d,J=8.5Hz,1H),7.87(dd,J=8.6,2.4Hz,1H),7.32–7.26(m,2H),6.96–6.91(m,3H),3.88–3.79(m,4H),3.23(brs,4H).HRMS(ESI)calcd 512.1663; found,512.1663.

[0274] Example 18: Synthesis of ethyl 4-(6-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-18)

[0275]

[0276] The synthetic method of reference example 1 has a yield of 37% and is a white solid. 1H NMR (300MHz, CDCl3) δ9.12(s,1H),8.93–8.92(m,1H),8.67(s,1H),8.55–8.52(m,2H),8.49(dd,J=2.4,0.8Hz,1H),8.26–8.22(m,1H),8. 14(dd,J=8.7,0.8Hz,1H),7.85(dd,J=8.7,2.4Hz,1H),4.18(q,J=7.1Hz,2H),3.70–3.51(m,8H),1.29(t,J=7.1Hz,3H).HRMS(ESI)calcd 508.1562; found,508.1556.

[0277] Example 19: Synthesis of tert-butyl 4-(6-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-19)

[0278]

[0279] The synthetic method of reference example 1 has a yield of 41% and is a white solid. 1 H NMR(300MHz, CDCl3)δ9.33(s,1H),9.11(d,J=2.0Hz,1H),8.92(s,1H),8.58–8.53(m,3H),8.24(d,J=8.6Hz,1H),8.1 3(dd,J=8.6,2.0Hz,1H),7.86(d,J=8.7Hz,1H),3.67–3.60(m,4H),3.51–3.47(m,4H),1.48(s,9H).HRMS(ESI)calcd 536.1875; found,536.1871.

[0280] Example 20: Synthesis of (6-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-20)

[0281]

[0282] P-19 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to obtain compound P-20 with a yield of 100% as a white solid. 1H NMR (400MHz, DMSO) δ11.24(s,1H),9.58–9.53(m,3H),8.88(d,J=3.3Hz,1H),8.78(s,1H),8.51(d,J=2.2Hz,1H),8 .43(d,J=8.5Hz,1H),8.21–8.17(m,2H),8.11–8.08(m,1H),3.79–3.76(m,3H),3.19–3.15(m,3H).HRMS(ESI)calcd 436.1350; found,436.1352.

[0283] Example 21: Synthesis of (2-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyrimidin-5-yl)(4-ethylpiperazin-1-yl)methanone (P-21)

[0284]

[0285] The synthetic method of reference example 1 has a yield of 37% and is a white solid. 1 H NMR(400MHz, CDCl3)δ9.11(s,1H),8.97–8.96(m,2H),8.78(s,2H),8.67(d,J=3.3Hz,1H),8.32–8.29(m,1H),8.13(d,J =8.5Hz,1H),3.88–3.55(m,4H),2.51–2.45(m,6H),1.12(t,J=7.2Hz,3H).HRMS(ESI)calcd465.1616; found,465.1614.

[0286] Example 22: Synthesis of tert-butyl 4-(2-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyrimidine-5-carbonyl)piperazine-1-carboxylate (P-22)

[0287]

[0288] Referring to the synthesis method of Example 1, the yield was 45%. 1 H NMR (300MHz, CDCl3) δ9.11(s,1H),8.98–8.97(m,1H),8.76(s,2H),8.67(d,J=3.4Hz,1H),8.57(s,1H) ,8.31(d,J=8.7Hz,1H),8.13(dd,J=8.5,0.6Hz,1H),3.72–3.47(m,8H),1.49(s,9H).HRMS(ESI)calcd 537.1827; found,537.1820.

[0289] Example 23: Synthesis of (2-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyrimidin-5-yl)(piperazin-1-yl)methanone hydrochloride (P-23)

[0290]

[0291] P-22 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to obtain compound P-23 with a yield of 100% as a white solid. 1 H NMR (400MHz, DMSO) δ10.98(s,1H),9.56(d,J=16.5Hz,3H),8.85(d,J=3.3Hz,1H),8.80(d,J=1.5Hz,1H),8.75(s ,2H),8.39(d,J=8.5Hz,1H),8.24(dd,J=8.4,1.6Hz,1H),3.83–3.78(m,4H),3.20–3.16(m,4H).HRMS(ESI)calcd 437.1303; found,437.1302.

[0292] Example 24: Synthesis of (5-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-2-yl)(4-ethylpiperazin-1-yl)methanone (P-24)

[0293]

[0294] The synthetic method of reference example 1 has a yield of 37% and is a white solid. 1 H NMR (400MHz, CDCl3) δ9.10 (s, 1H), 8.90–8.89 (m, 1H), 8.78 (dd, J = 2.7, 0.7Hz, 1H ),8.45(d,J=3.3Hz,1H),8.34(dd,J=8.6,2.7Hz,1H),8.24–8.21(m,1H),8.12(dd ,J=8.5,0.6Hz,1H),7.74(d,J=8.5Hz,1H),7.55(s,1H),3.87–3.76(m,4H),2.58– 2.46(m,6H),1.11(t,J=7.2Hz,3H).HRMS(ESI)calcd464.1663; found,464.1654.

[0295] Example 25: Synthesis of tert-butyl 4-(5-((4-(benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-2-yl)piperazine-1-carboxylate (P-25)

[0296]

[0297] The synthetic method of reference example 1 has a yield of 39% and is a white solid. 1 H NMR (400MHz, CDCl3) δ9.11(s,1H),8.91(d,J=1.5Hz,1H),8.78(d,J=2.6Hz,1H),8.46(d,J=3.3Hz,1H),8.35(dd,J=8.6,2.6Hz,1H) ,8.24–8.22(m,1H),8.13(d,J=8.5Hz,1H),7.79(d,J=8.6Hz,1H),7.44(s,1H),3.79–3.75(m,4H),3.58–3.48(m,4H),1.48(s,9H).

[0298] Example 26: Synthesis of (5-((4-(Benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-2-yl)(piperazin-1-yl)methanone hydrochloride (P-26):

[0299]

[0300] P-25 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to obtain compound P-26 with a yield of 100% as a white solid. 1 H NMR (400MHz, DMSO) δ10.44(s,1H),9.55(s,1H),9.48(d,J=6.5Hz,2H),9.02(d,J=2.5Hz,1H),8.80(d,J=3.5Hz,1H),8.74(t,J=1.3H z,1H),8.42(dd,J=8.6,2.3Hz,2H),8.19–8.16(m,1H),7.76(d,J=8.6Hz,1H),3.91–3.88(m,4H),3.19–3.14(m,4H).HRMS(ESI)calcd 436.1350; found,436.1350.

[0301] Example 27: Synthesis of (6-((4-(2-(dimethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-27)

[0302]

[0303] Step 1: Synthesis of intermediate P-27-1: Refer to the synthesis method of Example 1, the yield is 36%, white solid. 1 HNMR(300MHz, CDCl3)δ8.55–8.52(m,2H),8.47–8.45(m,2H),8.33–8.32(m,1H),7.87–7.81(m,2H),7.76 –7.73(m,1H),3.66–3.47(m,8H),3.26(s,6H),1.48(s,9H).HRMS(ESI)calcd579.2297; found,579.2291.

[0304] Step 2: Dissolve the intermediate P-27-1 (100 mg) in dichloromethane (15 mL), add 3 mL of 2M EA-HCl solution dropwise, stir for 8 hours, and concentrate to obtain compound P-27 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ11.22(s,1H),9.54(s,2H),8.84(d,J=3.5Hz,1H),8.51–8.50(m,1H),8.25(s,1H),8.20–8.12(m ,2H),8.06(d,J=8.3Hz,1H),7.88–7.85(m,1H),3.80–3.76(m,4H),3.27(s,6H),3.19–3.16(m,4H).HRMS(ESI)calcd 479.1772; found,479.1774.

[0305] Example 28: Synthesis of (6-((4-(2-(diethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-28)

[0306]

[0307] Step 1: Synthesis of intermediate P-28-1: Refer to the synthesis method of Example 1, the yield is 39%, white solid. 1HNMR(400MHz, CDCl3)δ9.39(s,1H),8.59–8.56(m,2H),8.52(d,J=3.5Hz,1H),8.29(t,J=1.4Hz,1H),7.86–7.80(m,2 H),7.72(d,J=8.2Hz,1H),3.67–3.58(m,8H),3.50–3.47(m,4H),1.48(s,9H),1.32(t,J=7.1Hz,6H).HRMS(ESI)calcd 607.2610; found,607.2600.

[0308] Step 2: Dissolve the intermediate P-28-1 (100 mg) in dichloromethane (15 mL), add 3 mL of 2M EA-HCl solution dropwise, stir for 8 hours, and concentrate to obtain compound P-28 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ11.35(s,1H),9.64(s,2H),8.85(d,J=3.3Hz,1H),8.53(s,1H),8.28(s,1H),8.18–8.04(m,3H),7 .87(d,J=8.3Hz,1H),3.82–3.70(m,4H),3.68–3.64(m,4H),3.19–3.15(m,4H),1.27(t,J=7.1Hz,6H).HRMS(ESI)calcd 507.2085; found,507.2089.

[0309] Example 29: Synthesis of (5-((4-(2-(dimethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)(4-ethylpiperazin-1-yl)methanone (P-29)

[0310]

[0311] The synthetic method of reference example 1 has a yield of 33% and is a white solid. 1 H NMR(400MHz, CDCl3)δ8.75(d,J=2.6Hz,1H),8.39–8.34(m,2H),8.31(t,J=1.4Hz,1H),7.86–7.83(m,1H),7.76–7 .73(m,2H),7.29(s,1H),3.88–3.76(m,4H),3.25(s,6H),2.61–2.45(m,6H),1.14–1.11(m,3H).HRMS(ESI)calcd 507.2085; found,507.2077.

[0312] Example 30: Synthesis of (5-((4-(2-(dimethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)(4-isopropylpiperazin-1-yl)methanone (P-30)

[0313]

[0314] Referring to the synthesis method of Example 1, the yield was 37%. 1 H NMR (400MHz, CDCl3) δ8.75(d,J=2.6Hz,1H),8.39–8.34(m,2H),8.31(s,1H),7.84(d,J=8.3Hz,1H),7.73(d,J=8.4Hz,2H), 7.41(s,1H),3.85–3.76(m,4H),3.25(s,6H),2.78–2.72(m,1H),2.65–2.54(m,4H),1.07(d,J=6.5Hz,6H).HRMS(ESI)calcd 521.2242; found,521.2240.

[0315] Example 31: Synthesis of tert-butyl 4-(5-((4-(2-(dimethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-1-yl)piperazine-1-carboxylate (P-31)

[0316]

[0317] The synthetic method of reference example 1 has a yield of 38% and is a white solid. 1 H NMR(400MHz, CDCl3)δ8.75(d,J=2.6Hz,1H),8.40–8.35(m,2H),8.32(d,J=1.7Hz,1H),7.85–7.83(m,1H),7.7 9–7.73(m,2H),7.33(s,1H),3.79–3.75(m,4H),3.57–3.48(m,4H),3.26(s,6H),1.48(s,9H).HRMS(ESI)calcd 579.2297; found,579.2290.

[0318] Example 32: Synthesis of (5-((4-(2-(dimethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)(piperazin-1-yl)methanone hydrochloride (P-32)

[0319]

[0320] P-31 (100 mg) was dissolved in dichloromethane (15 mL), 3 mL of 2M EA-HCl solution was added dropwise, stirred for 8 hours, and concentrated to obtain compound P-32 with a yield of 100% as a light yellow solid. 1 H NMR (400MHz, DMSO) δ10.42(s,1H),9.63(s,2H),8.98(d,J=2.5Hz,1H),8.76(d,J=3.5Hz,1H),8.45(dd,J=8.7,2.5Hz,1H), 8.25(s,1H),8.07(d,J=8.4Hz,1H),7.86–7.78(m,2H),3.92–3.88(m,4H),3.29(s,6H),3.18–3.13(m,4H).HRMS(ESI)calcd 479.1772; found,479.1771.

[0321] Example 33: Synthesis of (5-((4-(2-(diethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-2-yl)(4-ethylpiperazin-1-yl)methanone (P-33)

[0322]

[0323] Referring to the synthesis method of Example 1, the yield was 38%. 1 H NMR (400MHz, CDCl3) δ8.74(d,J=2.6Hz,1H),8.39–8.35(m,2H),8.29(s,1H),7.82(d,J=8.3Hz,1H),7.75–7.71(m,2H),7.32(s, 1H),3.87–3.77(m,4H),3.62(q,J=7.1Hz,4H),2.60–2.47(m,6H),1.32(t,J=7.1Hz,6H),1.12(t,J=7.2Hz,3H).HRMS(ESI)calcd 535.2398; found,535.2398.

[0324] Example 34: Synthesis of (5-((4-(2-(diethylamino)benzothiazol-5-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-2-yl)(4-isopropylpiperazin-1-yl)methanone (P-34)

[0325]

[0326] The synthetic method of reference example 1 has a yield of 35% and is a white solid. 1H NMR (400MHz, CDCl3) δ8.75(d,J=2.6Hz,1H),8.38–8.35(m,2H),8.28(s,1H),7.81(d,J=8.3Hz,1H),7.75–7.70(m,2H),7.43(s,1H),3.85 –3.75(m,4H),3.61(q,J=7.1Hz,4H),2.79–2.73(m,1H),2.66–2.55(m,4H),1.32(t,J=7.1Hz,6H),1.07(d,J=6.5Hz,6H).HRMS(ESI)calcd 549.2555; found,549.2547.

[0327] Example 35: Synthesis of 1-(4-(6-((4-(2-(dimethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-35)

[0328]

[0329] Compound A-12 (309 mg, 1.0 mmol) and B-15 (298 mg, 1.2 mmol) were dissolved in dioxane (10 mL), and then Pd2(dba)3 (45.8 mg, 0.05 mmol), BINAP (62.3 mg, 0.1 mmol), cesium carbonate (651.6 mg, 2.0 mmol) were added, argon was replaced three times, heated to 100 ° C, and reacted for 12 hours. Cooling, filtration, concentration, column chromatography, and compound P35 (193 mg, 37% yield) were obtained as a white solid. 1 H NMR (300MHz, DMSO) δ10.36(s,1H),8.70(d,J=3.8Hz,1H),8.53(d,J=1.8Hz,1H),8.40(dd,J=2.4,0.8Hz,1H),8.31(d,J=8.7Hz,1H),8.06 (dt,J=8.8,1.2Hz,1H),7.90(dd,J=8.7,2.4Hz,1H),7.59(d,J=8.6Hz,1H),3.55–3.47(m,8H),3.21(s,6H),2.03(s,3H).HRMS(ESI)calcd 521.1878; found,521.1880.

[0330] Example 36: Synthesis of (4-(cyclopropanecarboxyl)piperazin-1-yl)(6-((4-(2-(dimethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)methanone (P-36)

[0331]

[0332] Synthesis of Reference Example 35, yield 35%. 1 H NMR (300MHz, DMSO) δ10.33(s,1H),8.70(d,J=3.8Hz,1H),8.53(d,J=1.8Hz,1H),8.41(dd,J=2.4,0.8Hz,1H),8.34–8.31(m,1H),8.08–8.05(m, 1H),7.91(dd,J=8.7,2.4Hz,1H),7.59(d,J=8.6Hz,1H),3.76–3.49(m,8H),3.21(s,6H),2.03–1.96(m,1H),0.77–0.71(m,4H).HRMS(ESI)calcd 547.2034; found,547.2032.

[0333] Example 37: Synthesis of (6-((4-(2-(dimethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(4-arylpiperazin-1-yl)methanone (P-37)

[0334]

[0335] Synthesis of Reference Example 35, yield 32%. 1 H NMR (400MHz, CDCl3) δ8.52(dd,J=8.7,0.8Hz,1H),8.48(dd,J=2.4,0.8Hz,1H),8.45–8.44(m,2H),8.42(d,J=3.8Hz,1H),8.16–8.13(m,1H),7.87(dd ,J=8.7,2.3Hz,1H),7.65(d,J=8.6Hz,1H),7.32–7.28(m,2H),6.96–6.90( m,3H),3.89–3.77(m,4H),3.27(s,6H),3.25–3.20(m,4H).HRMS(ESI)calcd 555.2085; found,555.2084.

[0336] Example 38: Synthesis of ethyl 4-(6-((4-(2-(dimethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-38)

[0337]

[0338] Synthesis of Reference Example 35, yield 34%.1 H NMR (300MHz, CDCl3) δ8.52(dd,J=8.7,0.8Hz,1H),8.47–8.42(m,4H),8.17–8.13(m,1H),7.84(dd,J=8.7,2.3Hz,1H ),7.65(d,J=8.6Hz,1H),4.18(q,J=7.1Hz,2H),3.70–3.52(m,8H),3.28(s,6H),1.31–1.26(m,3H).HRMS(ESI)calcd 551.1984; found,551.1984.

[0339] Example 39: Synthesis of 1-(4-(6-((4-(2-(diethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-39)

[0340]

[0341] Synthesis of Reference Example 35, yield 30%. 1 H NMR(300MHz, CDCl3)δ8.68(s,1H),8.54(dd,J=8.8,0.8Hz,1H),8.45–8.41(m,3H),8.15–8.12(m,1H),7.86(dd,J=8.7,2.3Hz,1 H),7.63(d,J=8.6Hz,1H),3.72–3.54(m,12H),2.15(s,3H),1.33(t,J=7.1Hz,6H).HRMS(ESI)calcd549.2191; found,549.2188.

[0342] Example 40: Synthesis of (4-(cyclopropanecarboxyl)piperazin-1-yl)(6-((4-(2-(diethylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)methanone (P-40)

[0343]

[0344] Synthesis of Reference Example 35, yield 31%. 1H NMR (300MHz, CDCl3) δ8.89 (s, 1H), 8.56–8.52 (m, 2H), 8.45 (d, J = 3.8Hz, 1H), 8.43 ( d,J=1.8Hz,1H),8.13(ddd,J=8.6,1.9,1.0Hz,1H),7.86(dd,J=8.7,2.4Hz,1H),7. 63(d,J=8.6Hz,1H),3.74–3.60(m,12H),1.79–1.73(m,1H),1.33(t,J=7.1Hz,6H), 1.04–1.01(m,2H),0.85–0.80(m,2H).HRMS(ESI)calcd575.2347; found,575.2344.

[0345] Example 41: Synthesis of 1-(4-(6-((4-(2-(cyclopentylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-41)

[0346]

[0347] Synthesis of Reference Example 35, yield 41%. 1 H NMR (400MHz, CDCl3) δ8.53–8.50(m,2H),8.45(dd,J=2.4,0.8Hz,1H),8.43–8.42(m,2H),8.13–8.10(m,1H),7.84(dd,J=8.7,2.4Hz ,1H),7.63(d,J=8.6Hz,1H),5.82(s,1H),4.11–4.05(m,1H),3.73–3.53(m,8H),2.24–2.17(m,2H),2.15(s,3H),1.83–1.68(m,6H). 13 C NMR (126MHz, CDCl3) δ168.36,167.73,167.27,155.27,154.98,153.90,151.55,151.05,150.98,149.52,147.08,146.93,137.42,137. 31,130.89,126.74,126.69,124.93,124.89,124.31,121.53,117.65,110.89,55.71,39.76,39.60,39.43,39.26,39.10,23.25,21.16.

[0348] Example 42: Synthesis of (4-(6-((4-(2-(cyclopentylamino)benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)(cyclopropyl)methanone (P-42)

[0349]

[0350] Synthesis of Reference Example 35, yield 43%. 1 H NMR (400MHz, CDCl3) δ8.65(s,1H),8.53–8.51(m,1H),8.47–8.41(m,3H),8.11–8.09(m,1H),7.85(dd,J=8.7,2.4Hz,1H),7.63(d,J=8.6 Hz,1H),5.89(s,1H),4.12–4.06(m,1H),3.78–3.64(m,8H),2.18–2.14(m,2H),1.80–1.66(m,7H),1.05–1.01(m,2H),0.84–0.80(m,2H). 13 C NMR (126MHz, CDCl3) δ171.18,167.71,167.26,155.26,154.99,153.90,151.54,151.03,150.96,149.52,147.13,146.9 6,137.40,137.28,130.88,126.68,124.93,124.89,124.31,121.50,117.65,110.78,55.71,32.22,23.24,10.27,7.05.

[0351] Example 43: Synthesis of (6-((4-(Benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone (P-43)

[0352]

[0353] Refer to the synthesis method of Example 35, the yield is 41%, white solid. 1 H NMR(400MHz, CDCl3)δ9.62(s,1H),9.15(s,1H),8.76(s,1H),8.62–8.59(m,2H),8.54–8.51(m,1H),8.33–8.2 8(m,2H),7.89–7.85(m,1H),3.80–3.52(m,4H),2.77–2.72(m,1H),2.59–2.49(m,4H),1.06(d,J=6.7Hz,6H).13 CNMR(126MHz,DMSO)δ166.77,159.14,155.19,155.17,154.37,153.61,151.74,150.69,150.62,149.71,147.76, 147.55,146.85,137.20,134.14,129.91,126.58,126.54,124.83,123.54,123.48,123.16,110.93,53.61,17.97.

[0354] Example 44: Synthesis of 1-(4-(6-((4-(benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-44)

[0355]

[0356] Synthesis of Reference Example 35, yield 44%. 1 H NMR(400MHz, CDCl3)δ9.16(s,1H),8.78(s,1H),8.53–8.50(m,2H),8.47–8.44(m,2H) ,8.34–8.28(m,2H),7.86(dd,J=8.7,2.3Hz,1H),3.73–3.53(m,9H),2.15(s,3H).13C NMR (101MHz, DMSO) δ168.92,167.80,159.73,155.74,155.71,154.95,154.35,152.58,151.28,151.19,150.04,148.37,1 48.11,147.60,137.93,134.72,130.46,130.41,127.16,127.10,125.07,124.12,124.05,123.73,111.50,46.01,21.73.

[0357] Example 45: Synthesis of (4-(6-((4-(Benzothiazol-6-yl)-5-fluoropyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)(cyclopropyl)methanone (P-45)

[0358]

[0359] Synthesis of Reference Example 35, yield 42%. 1H NMR (400MHz, CDCl3) δ9.16(s,1H),8.78(s,1H),8.52(dd,J=6.0,2.7Hz,2H),8.46(d,J=2.3Hz,1H),8.35–8.28( m,3H),7.87(dd,J=8.7,2.4Hz,1H),3.81–3.62(m,8H),1.77–1.71(m,1H),1.04–1.02(m,2H),0.84–0.81(m,2H). 13 CNMR(126MHz,DMSO)δ171.21,167.22,159.11,155.12,155.10,154.38,153.77,151.75,150.70,150.62,149.72,147.73, 147.52,147.06,137.44,134.15,129.87,129.83,126.57,126.52,124.48,123.51,123.45,123.14,110.93,10.30,7.06.

[0360] Example 46: Synthesis of 4-(Benzothiazol-6-yl)-N-(5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)-5-methylpyrimidin-2-amine (P-46)

[0361]

[0362] Synthesis of Reference Example 35, yield 42%. 1 H NMR (400MHz, CDCl3) δ9.12(s,1H),8.45(s,1H),8.42(d,J=8.6Hz,1H),8.30–8.24(m,4H),7.82(dd,J=8. 5,1.7Hz,1H),7.61(d,J=8.6Hz,1H),3.55(s,2H),3.33–2.86(m,9H),2.34(s,3H),1.38(d,J=6.8Hz,6H).

[0363] Example 47: Synthesis of tert-butyl 4-(6-((4-(benzothiazol-6-yl)-5-methylpyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-47)

[0364]

[0365] Synthesis of Reference Example 35, yield 34%. 1H NMR(400MHz, CDCl3)δ9.12(s,1H),8.53(dd,J=8.7,0.8Hz,1H),8.48–8.46(m,2H),8.44(dd,J=2.4,0.8Hz,1H),8.28 –8.26(m,2H),7.82(dd,J=8.6,1.7Hz,1H),7.76(dd,J=8.7,2.3Hz,1H),3.66–3.45(m,8H),2.36(s,3H),1.48(s,9H).

[0366] Example 48: Synthesis of (6-((4-(Benzothiazol-6-yl)-5-methylpyrimidin-2-yl)amine)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone (P-48)

[0367]

[0368] Synthesis of Reference Example 35, yield 39%. 1 H NMR(400MHz, CDCl3)δ9.12(s,1H),8.51–8.49(m,1H),8.46(s,1H),8.42(d,J=2.2Hz,1H),8.28–8.26(m,3H),7.82(dd,J=8.6,1.6 Hz,1H),7.77(dd,J=8.7,2.3Hz,1H),3.75–3.55(m,4H),2.77–2.71(m,1H),2.59–2.36(m,4H),2.36(s,3H),1.06(d,J=6.5Hz,6H).

[0369] Example 49: Synthesis of (6-((4-(Benzothiazol-6-yl)-5-methylpyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-49)

[0370]

[0371] P47 (100 mg) was dissolved in dichloromethane (15 mL), and 3 mL of 2M EA-HCl solution was added dropwise. The mixture was stirred for 8 hours and concentrated to obtain compound P49 with a yield of 100% as a white solid. 1H NMR (400MHz, DMSO) δ11.83(s,1H),9.68(s,2H),9.56(s,1H),8.73(s,1H),8.62(d,J=1.7Hz,1H),8.56(d,J=2.2Hz,1H),8 .27(d,J=8.5Hz,1H),8.20(dd,J=8.9,2.1Hz,1H),7.96–7.91(m,2H),3.80–3.76(m,4H),3.18–3.16(m,4H),2.42(s,3H).

[0372] Example 50: Synthesis of 4-(Benzothiazol-6-yl)-N-(5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)-5-methoxypyrimidin-2-amine (P-50)

[0373]

[0374] Reference Example 35, yield 52%. H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 8.80 (dd, J = 1.7, 0.7 Hz, 1H), 8.37 (dd, J = 8.6, 0.9 Hz, 1H), 8.35-8.32 (m, 2H), 8.24 (dd, J = 8.6, 0.6 Hz, 1H), 8.21-8.20 (m, 1H), 8.03 (s, 1H), 7.68 (dd, J = 8.6, 2.3 Hz, 1H), 3.95 (s, 3H), 3.48 (s, 2H), 2.68-2.49 (m, 9H), 1.05 (d, J = 6.5 Hz, 6H).

[0375] Example 51: Synthesis of tert-butyl 4-(6-((4-(benzothiazol-6-yl)-5-methoxypyrimidin-2-yl)amine)nicotinoyl)piperazine-1-carboxylate (P-51)

[0376]

[0377] Synthesis of Reference Example 35, yield 43%. 1 H NMR(400MHz, CDCl3)δ9.12(s,1H),8.79(d,J=1.7Hz,1H),8.53–8.49(m,2H),8.45(dd,J=2.4,0.9Hz,1H),8.39(s,1H),8.3 2(dd,J=8.7,1.7Hz,1H),8.25(d,J=8.7Hz,1H),7.80(dd,J=8.7,2.4Hz,1H),3.97(s,3H),3.65–3.46(m,8H),1.48(s,9H).

[0378] Example 52: Synthesis of (6-((4-(Benzothiazol-6-yl)-5-methoxypyrimidin-2-yl)amine)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone (P-52)

[0379]

[0380] Synthesis of Reference Example 35, yield 45%. 1 H NMR(400MHz, CDCl3)δ9.11(s,1H),8.80–8.79(m,1H),8.48(dd,J=8.7,0.9Hz,1 H),8.44(dd,J=2.4,0.8Hz,1H),8.40(s,1H),8.38(s,1H),8.32(dd,J=8.6,1.7 Hz,1H),8.25(dd,J=8.7,0.6Hz,1H),7.81(dd,J=8.7,2.3Hz,1H),3.96(s,3H), 3.81–3.56(m,4H),2.79–2.71(m,1H),2.61–2.52(m,4H),1.07(d,J=6.5Hz,6H).

[0381] Example 53: Synthesis of (6-((4-(Benzothiazol-6-yl)-5-methoxypyrimidin-2-yl)amine)pyridin-3-yl)(piperazin-1-yl)methanone hydrochloride (P-53)

[0382]

[0383] P51 (100 mg) was dissolved in dichloromethane (15 mL), and 3 mL of 2M EA-HCl solution was added dropwise. The mixture was stirred for 8 hours and concentrated to obtain compound P53 with a yield of 100% as a white solid. 1 H NMR (400MHz, DMSO) δ12.05(s,1H),9.76(s,2H),9.58(s,1H),8.95(d,J=1.5Hz,1H),8.66(s,1H),8.58(d,J =2.2Hz,1H),8.30–8.24(m,3H),7.91(d,J=9.0Hz,1H),4.06(s,3H),3.82–3.76(m,4H),3.19–3.16(m,4H).

[0384] Example 54: Synthesis of (6-((4-(Benzothiazol-6-yl)pyrimidin-2-yl)amine)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone (P-54)

[0385]

[0386] Synthesis of Reference Example 35, yield 42%. 1 H NMR (400MHz, CDCl3) δ9.13 (s, 1H), 8.76 (d, J = 1.6Hz, 1H), 8.62 (d, J = 5.3Hz, 1 H),8.59(d,J=8.6Hz,1H),8.44(d,J=2.3Hz,1H),8.27(d,J=8.6Hz,1H),8.22( dd,J=8.6,1.6Hz,1H),7.86(dd,J=8.6,2.3Hz,1H),7.37(d,J=5.2Hz,1H),3. 80–3.55(m,4H),2.79–2.72(m,1H),2.60–2.52(m,4H),1.07(d,J=6.5Hz,6H). 13 C NMR (126MHz, DMSO) δ167.38,163.81,159.73,159.60,159.16,155.23,154.24,147.44,1 37.84,134.95,134.07,125.64,125.34,123.79,122.10,112.14,110.35,54.29,18.50.

[0387] Example 55: Synthesis of 5-fluoro-N-(5-((4-isopropylpiperazin-1-yl)methyl)pyridin-2-yl)-4-(2-methylbenzothiazol-6-yl)pyrimidin-2-amine (P-55)

[0388]

[0389] Synthesis of Reference Example 35, yield 51%. 1 H NMR (400MHz, CDCl3) δ8.64(s,1H),8.46(d,J=3.5Hz,1H),8.38(d,J=8.5Hz,1H),8.33–8.21(m,3H),8.08(d ,J=8.6Hz,1H),7.70(d,J=8.6Hz,1H),3.54(s,2H),2.91(s,3H),2.88–2.50(m,9H),1.24(d,J=17.2Hz,6H).

[0390] Example 56: Synthesis of (6-((5-fluoro-4-(2-methylbenzothiazol-6-yl)pyrimidin-2-yl)amine)pyridin-3-yl)(4-isopropylpiperazin-1-yl)methanone (P-56)

[0391]

[0392] Synthesis of Reference Example 35, yield 42%. 1 H NMR (400MHz, CDCl3) δ8.64(d,J=1.7Hz,1H),8.48–8.46(m,2H),8.44(dd,J=2.3,0.8Hz,1H),8.30(s,1H),8.26–8.24(m,1H),8.09(d,J =8.6Hz,1H),7.84(dd,J=8.6,2.3Hz,1H),3.80–3.55(m,4H),2.91(s,3H),2.78–2.72(m,1H),2.61–2.50(m,4H),1.07(d,J=6.4Hz,6H). 13 C NMR (126MHz, CDCl3) δ170.03,167.97,155.12,155.10,153.82,152.28,151.79,151.72,150.24,147.54,147.35,147 .14,137.92,136.27,129.74,129.69,126.80,126.75,125.03,122.65,122.59,122.57,111.03,54.58,20.43,18.37.

[0393] Example 57: Synthesis of 1-(4-(6-((5-fluoro-4-(2-methylbenzothiazol-6-yl)pyrimidin-2-yl)amine)nicotinoyl)piperazin-1-yl)ethyl-1-one (P-57)

[0394]

[0395] Synthesis of Reference Example 35, yield 38%. 1 H NMR (400MHz, CDCl3) δ8.64 (d, J = 1.7Hz, 1H),

[0396] 8.53–8.46(m,4H),8.26–8.24(m,1H),8.09(d,J=8.6Hz,1H),7.86(dd,J=8.7,2.4Hz,1H),

[0397] 3.76–3.54(m,8H),2.91(s,3H),2.15(s,3H). 13 C NMR (126MHz, CDCl3) δ170.13,169.22,

[0398] 168.49,155.06,154.33,152.28,151.81,151.74,150.23,147.68,147.38,147.17,137.98,136.25,

[0399] 129.67,129.62,126.77,126.72,124.07,122.65,122.59,122.56,111.16,46.16,41.49,21.39, 20.42.

[0401] Example 58: Synthesis of (4-(cyclopropylcarbonyl)piperazin-1-yl)(6-((5-fluoro-4-(2-methylbenzothiazol-6-yl)pyrimidin-2-yl)amine)pyridin-3-yl)methanone (P-58)

[0402]

[0403] Synthesis of Reference Example 35, yield 30%. 1 H NMR (400MHz, CDCl3) δ8.70(s,1H),8.64(d,J=1.7Hz,1H),8.54–8.50(m,3H),8.26–8.23(m,1H),8.09(d,J=8.6H z,1H),7.87(dd,J=8.7,2.4Hz,1H),3.79–3.63(m,8H),2.91(s,3H),1.78–1.72(m,1H),1.05–1.01(m,2H),0.85–

[0404] 0.80(m,2H). 13 C NMR (101MHz, DMSO) δ170.86,167.79,155.71,155.68,155.00,154.37,154.37,152.54,151.31,151.22,150.01,148.26, 147.62,137.92,136.29,129.71,129.66,127.07,127.01,125.04,123.49,123.41,122.60,111.47,21.23,10.83,7.62.

[0405] Biological evaluation experiment:

[0406] 1. DYRK2 kinase activity analysis method

[0407] To investigate the inhibitory effect of Example compounds P-1 to P-40 on DYRK2 kinase, we first prepared a reaction buffer containing 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.01% Brij35, 0.02 mg / mL BSA, 0.1 mM Na3VO4, 2 mM DTT, and 1% DMSO. Subsequently, DYRK2 kinase and DYRKtide substrate were added to the reaction buffer and gently mixed. The test compound was placed in the reaction mixture and added 33 The reaction was initiated by P-ATP. The reaction was then observed on P81 ion exchange paper and incubated for 2 hours at room temperature. Finally, the residual radioactive phosphorylated substrate on the filter paper was measured to calculate the residual DYRK2 activity of the test compound group relative to the DMSO control group.

[0408] Measured IC 50 The values ​​are shown in Table 1 below. From the experimental results, it can be seen that the example compounds of the present invention have strong inhibitory activity on DYRK2 kinase activity.

[0409] Table 1 IC of the compounds of the present invention against DYRK2 kinase activity 50 Measurements

[0410]

[0411]

[0412] Most of the compounds prepared by the present invention have strong inhibitory activity against DYRK2 kinase, and the IC of most of the compounds against DYRK2 kinase is 50 The measured value is less than 1000 nM, wherein the IC of Examples 20, 24, 25, 26, 27, 29, 30, 32, 36, 39, 40 50 The measured value is less than 20 nM. It can be seen from the table that the compound of the present invention has very good inhibitory activity on DYRK2 kinase.

[0413] 2. Cell proliferation inhibition activity test

[0414] The inhibitory effect of the compound on the proliferation of prostate cancer DU145 and 22Rv1 cells was determined according to the CCK-8 method. The preferred compound Example 20 or Example 40 or Example 39 was co-incubated with DU145 or 22Rv1 cells in a 96-well plate for 72 hours, and then CCK8 reagent was added. The cells were incubated at 37° C. and 5% CO2 for 2 hours. After the incubation, the absorbance value at 450 nm was measured by an ELISA instrument, and then the half-inhibitory concentration IC of the compound's inhibitory activity on cell proliferation was obtained by fitting using GraphPad Prism 6. 50 .

[0415]

[0416] As can be seen from the table, the compounds of Example 20 and Example 40 significantly inhibited the proliferation of prostate cancer DU145 and 22Rv1 cells, see the attached figure of the specification Figure 1 and Figure 2 .

[0417] 3. Acute toxicity test

[0418] 1. Acute toxicity test of compound in Example 20

[0419] ICR mice were divided into 5 groups, 1 control group and 4 treatment groups, and Example 20 was gavaged, with 6 mice in each group. The control group was gavaged with an equal amount of normal saline, and the four treatment groups were gavaged with Example 20 compound once at a dose of 1000 mg / kg, 2500 mg / kg, 5000 mg / kg, and 10000 mg / kg, respectively. The poisoning symptoms and death of the mice were recorded, and the dead animals were autopsied. The observation period was 14 days.

[0420] The results showed that within 12 hours after administration, no abnormality was observed in the animals. No animal death was observed within 24 hours of administration, and no animal death was observed after the 14th day of administration. The mice were dissected and the main organs such as the heart, liver, spleen, lungs, and kidneys were weighed. It was found that the weight of the main organs in the administration group was no different from that in the control group. Therefore, Example 20 has no obvious toxic side effects and is safe. See the attached drawings of the specification. Figure 3 .

[0421] 2. Acute toxicity test of compound in Example 40

[0422] ICR mice were divided into 5 groups, 1 control group and 4 administration groups, and Example 20 was gavaged, with 6 mice in each group. The control group was gavaged with an equal amount of normal saline, and the four administration groups were gavaged with Example 40 compound once at a dose of 1000 mg / kg, 2500 mg / kg, 5000 mg / kg, and 10000 mg / kg, respectively. The poisoning symptoms and death of the mice were recorded, and the dead animals were autopsied. The observation period was 14 days.

[0423] The results showed that within 12 hours after administration, no abnormality was observed in the animals. No animal death was observed within 24 hours of administration, and no animal death was observed after the 14th day of administration. The mice were dissected and the main organs such as the heart, liver, spleen, lungs, and kidneys were weighed. It was found that the weight of the main organs in the administration group was no different from that in the control group. Therefore, Example 40 has no obvious toxic side effects and is safe. See the attached figure of the specification. Figure 4 .

[0424] IV. In vivo efficacy test against prostate cancer

[0425] 1. Example 20 Anti-prostate cancer in vivo efficacy test

[0426] DU145 cells were inoculated subcutaneously in the right axilla of BALB / c nude mice and the tumors were grown to 85 mm. 3 24 nude mice with good growth and uniform tumor size were selected and divided into 4 groups, 6 mice in each group, namely, model group, low-dose group (100 mg / kg) of Example 20, high-dose group (200 mg / kg) of Example 20, and positive drug enzalutamide group (100 mg / kg), and the drug was administered once a day. The tumor diameter was measured once every other day, and the nude mice were weighed while measuring the tumor diameter. The nude mice were euthanized 21 days after administration, and the tumor mass was surgically removed and weighed.

[0427] The experimental results showed that the T / C (%) of the low-dose group of Example 20 for human prostate cancer cell DU145 nude mouse transplanted tumor was 50.9%, and the tumor inhibition rate was 48.7%; the T / C (%) of the high-dose group of Example 20 for human prostate cancer cell DU145 nude mouse transplanted tumor was 34.4%, and the tumor inhibition rate was 65.3%. The T / C (%) of the positive drug enzalutamide group for human prostate cancer cell DU145 nude mouse transplanted tumor was 42.0%, and the tumor inhibition rate was 57.8%; and the body weight of the nude mice in each group did not decrease significantly during the administration period, see the attached figure of the specification Figure 5 .

[0428] 2. Example 40 Anti-prostate cancer in vivo efficacy test

[0429] DU145 cells were inoculated subcutaneously in the right axilla of BALB / c nude mice and the tumors were grown to 85 mm. 3 28 nude mice bearing tumors with good growth status and good uniformity of tumor size were selected and divided into 4 groups, 7 mice in each group, namely, model group, low-dose group (80 mg / kg) of Example 40, high-dose group (200 mg / kg) of Example 40, and positive drug enzalutamide group (80 mg / kg), and the drugs were administered once a day. The tumor diameter was measured once every other day, and the nude mice were weighed while measuring the tumor diameter. The nude mice were euthanized 21 days after administration, and the tumor mass was surgically removed and weighed.

[0430] The experimental results show that the T / C (%) of the low-dose group of Example 40 on the human prostate cancer cell DU145 nude mouse transplant tumor was 55.3%, and the tumor inhibition rate was 43.6%; the T / C (%) of the high-dose group of Example 20 on the human prostate cancer cell DU145 nude mouse transplant tumor was 34.8%, and the tumor inhibition rate was 65.0%. The T / C (%) of the positive drug enzalutamide group on the human prostate cancer cell DU145 nude mouse transplant tumor was 38.8%, and the tumor inhibition rate was 60.9%, see the attached figure of the specification Figure 6 .

Claims

1. A compound represented by formula (PI) or a pharmaceutically acceptable salt thereof, in: X is independently selected from: C(O) or -(CH2) n -, n is 1; A is a N atom, B and C are C atoms; or A and B are N atoms, C is a C atom; or A and B are C atoms, C is a N atom; R1 is independently selected from: hydrogen, deuterium or -NR4R5, wherein R4 and R5 are independently selected from: C1-C8 alkyl; R2 is independently selected from hydrogen, deuterium, halogen, C1-C8 alkyl or C1-C8 alkoxy; R3 are independently selected from hydrogen, deuterium, C1-C8 alkyl, C6-C 10 Aryl or -C(O)R6; R6 are independently selected from C1-C8 alkyl, C1-C8 alkoxy or C3-C8 cycloalkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: in: The X are independently selected from C(O) or -(CH2) n -, n is 1; A is a N atom, B and C are C atoms; or A and B are N atoms, C is a C atom; or A and B are C atoms, C is a N atom; The R1 is independently selected from hydrogen, -NR4R5, wherein R4 and R5 are selected from C1-C6 alkyl; The R2 are independently selected from hydrogen, halogen, C1-C6 alkyl or C1-C6 alkoxy; The R3 are independently selected from hydrogen, C1-C6 alkyl, C6-C 10 Aryl or -C(O)R6; The R6 are independently selected from C1-C6 alkyl, C1-C6 alkoxy or C3-C6 cycloalkyl.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: in: The X's are independently selected from C(O) or -CH2-; A is a N atom, B and C are C atoms; or A and B are N atoms, C is a C atom; or A and B are C atoms, C is a N atom; The R1 is selected from hydrogen or -NR4R5, wherein R4 and R5 are independently selected from methyl, ethyl, propyl, cyclopentyl or cyclohexyl; The R2 are independently selected from hydrogen, methyl, ethyl, propyl, methoxy or fluorine; The R3 are independently selected from hydrogen, methyl, ethyl, propyl, n-butyl, isobutyl or -C(O)R6; The R6 are independently selected from methyl, ethyl, methoxy, ethoxy or cyclopropyl.

4. The compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, characterized in that: A compound selected from the following structures or a pharmaceutically acceptable salt thereof:

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: The pharmaceutically acceptable salt is a salt formed by the compound of formula (PI) and hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, acetic acid, trichloroacetic acid, propionic acid, butyric acid, maleic acid, p-toluenesulfonic acid, malic acid, malonic acid, cinnamic acid, citric acid, fumaric acid, camphoric acid, aspartic acid or tartaric acid.

6. A method for preparing the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, characterized in that: The method comprises the steps of coupling reaction between an intermediate compound (A) and an intermediate compound (B) under the action of a catalyst: wherein the substituents of X, A, B, C, R1, R2 and R3 are defined as any one of claims 1 to 5; Wherein, the catalyst is a palladium catalyst; the reaction is carried out under an argon protective atmosphere; the reaction temperature is 55-125° C., and the reaction time is 5-24 hours.

7. A pharmaceutical composition comprising the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof.

8. Use of the compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating cancer-related diseases, wherein the cancer-related disease is lung cancer, breast cancer, prostate cancer or multiple myeloma.